

1 **Global Assessment of Palliative Care Need:**
2 **Serious Health-Related Suffering Measurement Methodology**
3 Xiaoxiao J Kwete^{†, 1,2}, Afsan Bhadelia^{†, 1,3}, Héctor Arreola-Ornelas,^{1,4,5,6} Oscar
4 Mendez,⁵ William E. Rosa,^{1,7} Stephen Connor,⁸ Julia Downing,⁹ Dean Jamison,¹⁰
5 David Watkins,¹¹ Renzo Calderon,¹ Jim Cleary,¹² Joe Friedman,¹³ Liliana De Lima,¹⁴
6 Christian Ntizimira,¹⁵ Tania Pastrana,¹⁶ Pedro E. Pérez-Cruz,¹⁷ Dingle Spence,¹⁸ M.R.
7 Rajagopal,¹⁹ Valentina Vargas Enciso,¹ Eric L. Krakauer^{‡, 20} Lukas Radbruch^{‡, 21}
8 Felicia Marie Knaul^{‡1,5,22,23}

9
10 [†] *Joint first authors*

11 [‡] *Joint last/senior authors*

12
13 ¹ University of Miami Institute for Advanced Study of the Americas, University of
14 Miami, Miami, FL, USA

15 ² Yangzhou Philosophy and Social Science Research and Communication Center,
16 Yangzhou, China

17 ³ Department of Public Health, College of Health and Human Sciences, Purdue
18 University, West Lafayette, IN, USA

19 ⁴ Institute for Obesity Research & School of Government and Public Transformation,
20 Tecnológico de Monterrey, Monterrey, Mexico.

21 ⁵ Tomatelo a Pecho, A.C., Mexico City, Mexico.

22 ⁶ Fundación Mexicana para la Salud (FUNSALUD), Mexico City, México.

23 ⁷ Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering
24 Cancer Center, New York, NY, USA

25 ⁸ Worldwide Hospice Palliative Care Alliance, London, UK

26 ⁹ International Children's Palliative Care Network, Bristol, UK

27 ¹⁰ University of California, San Francisco, USA

28 ¹¹ Department of Global Health, University of Washington, Seattle, WA, USA

29

30 ¹² Indiana University School of Medicine, Indianapolis, IN, USA

31 ¹³ University of California in Los Angeles, School of Medicine, Los Angeles, CA,
32 USA

33 ¹⁴ International Association of Hospice and Palliative Care, Houston, TX, USA

34 ¹⁵ African Center for Research on End of Life Care, Kigali, Rwanda

35 ¹⁶ Department for Palliative Medicine, RWTH Aachen University, Germany

36 ¹⁷ Programa Medicina Paliativa y Cuidados Continuos, Facultad de Medicina,
37 Pontificia Universidad Católica de Chile (PUC), Santiago, Chile

38 ¹⁸ University of the West Indies, Mona, Jamaica

39 ¹⁹ Pallium India Trust, Kerala, India

40 ²⁰ Department of Global Health & Social Medicine, Harvard Medical School, Boston,
41 MA, USA

42 ²¹ University of Bonn, Bonn, Germany

43 ²² Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami,

44 USA

45 ²³ Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, USA

46

47 **Abstract**

48 Inequities and gaps in palliative care access are a serious impediment to health systems
49 especially low- and middle-income countries and the accurate measurement of need
50 across health conditions is a critical step to understanding and addressing the issue.

51 Serious Health-related Suffering (SHS) is a novel methodology to measure the
52 palliative care need and was originally developed by The Lancet Commission on
53 Global Access to Palliative Care and Pain Relief. In 2015, the first iteration – SHS 1.0
54 – was estimated at over 61 million people worldwide experiencing at least 6 billion
55 days of SHS annually as a result of life-limiting and life-threatening conditions. In this
56 paper, an updated methodology - SHS2.0 - is presented building on the work of the
57 Lancet Commission and detailing calculations, data requirements, limitations, and
58 assumptions. The updates to the original methodology focus on measuring the number
59 of people who die with (decedents) or live with (non-decedents) SHS in a given year
60 to assess the number of people in need of palliative care across health conditions and
61 populations. Detail on the methodology for measuring the number of days of SHS that
62 was pioneered by the Lancet Commission, is also shared, as this second measure is
63 essential for determining the health system responses that are necessary to address
64 palliative care need and must be a priority for future methodological work on SHS.
65 The discussion encompasses opportunities for applying SHS to future policy making
66 assessment of future research priorities particularly in light of the dearth of data from
67 low- and middle-income countries, and sharing of directions for future work to
68 develop SHS 3.0.

69

70 **Keywords:** *serious health-related suffering; palliative care; suffering measurement;*
71 *palliative care need*

72

73

74 **I. Background**

75 Over 60 million people annually experience serious health-related suffering (SHS)
76 that is amenable to palliative care. However, most reside in low-resource and rural
77 areas with nonexistent or inadequate palliative care services, and limited access to
78 medicines and technologies that can reduce SHS,(1) emblematic of the tragedy and
79 injustice of overall disparities in healthcare. Palliative care is a core component of
80 universal health coverage (UHC), making the lack of access to palliative care a
81 serious impediment to SDG Goal 3, namely, to “ensure healthy lives and promote
82 well-being for all at all ages”(2, 3) and to achieving Sustainable Development Goal 10
83 focused on reducing inequality within and among all countries.(1, 2)

84

85

Efforts to address this global health failing and to close the divide in access to
palliative care have been thwarted by various factors.(1, 4) One is the dearth of

86 methods and data to quantify global palliative care need and this was a major area of
87 work of The Lancet Commission on Global Access to Palliative Care and Pain Relief
88 (hereafter referred to as Lancet Commission or the Commission) in developing SHS.
89 Although evidence is required to develop appropriate and targeted recommendations
90 for closing gaps in access to palliative care, measurement of the burden of SHS has
91 not kept pace with progress in measuring the burden of disease.(1, 5) A scientific
92 focus on measurement of SHS(6, 7) is a necessary complement to existing measures
93 of the burden of disease such as quality-adjusted life years (QALYs) and disability
94 adjusted life years (DALYs). Further, measurement of SHS has value and purpose in
95 its own right as a global health issue and as part of efforts to achieve the SDGs.

96 The Lancet Commission report presented a breakthrough by introducing the
97 concept of serious health-related suffering (SHS) to quantify the global and country-
98 specific need for palliative care and pain relief in terms of both the number of
99 individuals who experience SHS (population in need of palliative care services), and
100 the number of days of each type of SHS (as an input to develop more effective health
101 system responses to address palliative care need) in a given year. Building on more
102 limited efforts to measure population-based need for palliative care in previous
103 publications,(4) the Commission estimated the 2015 global burden of SHS at 61
104 million: 25.5 million people who died - 45% of the 56.2 million deaths worldwide -
105 and an additional 35.5 million people who experienced an SHS-associated condition
106 and did not die in that year, with at least 6 billion symptom days experienced by those
107 people. The estimates were calculated by a systematic process documented briefly in
108 the Lancet Commission report and in its entirety in an white paper.(1, 8)

109 The Lancet Commission Report has been cited by over 1000 research article
110 publications as of this writing, and the data has been used by various international
111 organizations and initiatives including the International Narcotic Control Board
112 (INCB), the Worldwide Hospice Palliative Care Alliance (WHPCA), and the Disease
113 Control Priorities (3rd edition), as well as various country champions of palliative
114 care in their evidence generation, policy making and advocacy endeavors.(9-11)
115 The Lancet Commission Secretariat was transformed into an interdisciplinary
116 Research Hub on Global Access to Palliative Care and Pain Relief - jointly led by the
117 University of Miami Institute for Advanced Study of the Americas and the
118 International Association for Hospice and Palliative Care - to promote evidence
119 generation, dissemination, and translation to policy and practice to achieve universal
120 access to palliative care. The research hub built on the original Commission
121 methodology – SHS1.0 - to generate the next iteration – SHS 2.0.

122 In this paper, the SHS 2.0 methodology is summarized, exclusively dealing with
123 measuring the number of people who die with (decedents) or live with (non-decedents)
124 SHS. The assumptions, strengths, and weaknesses of both the original and the 2.0
125 iteration for measuring people with SHS are discussed. The methodology for
126 measuring the number of days of SHS is also detailed. Pioneered by the Lancet
127 Commission, measuring days with SHS is essential for determining the health system

128 responses to palliative care need and although not undertaken as part of SHS2.0, must
129 be a priority for future methodological work on SHS. A guide to calculating the
130 burden of SHS is provided, including specific instructions on measuring the number
131 of people who die with (decedents) or live with (non-decedents) SHS and the number
132 of symptom days they experience annually, as well as secondary indicators that may
133 be constructed with the SHS database. The paper concludes with a discussion on the
134 potential applications of SHS data for researchers, policymakers, and practitioners as
135 well as directions for future work and priorities for developing SHS 3.0. It is linked to
136 another methods paper on measuring distributed opioid morphine equivalent (DOME)
137 and comparing DOME against the need for palliative care (SHS).

138

139 **II. Defining and measuring SHS**

140 Serious health-related suffering, as defined by the Lancet Commission, is the “pain,
141 suffering, and severe distress associated with life-threatening or life-limiting health
142 conditions and with end of life”(1) that cannot be relieved without medical
143 intervention and that is potentially amenable to relief through palliative care. SHS is
144 not bound by time or prognosis and includes complex, chronic or acute, life
145 threatening or life-limiting health conditions.(12)

146 The definition of palliative care adopted by the Lancet Commission is the one
147 used by the World Health Organization (WHO) at the time: “an approach that
148 improves the quality of life of patients and their families facing the problems
149 associated with life-threatening illness through the prevention and relief of suffering
150 by means of early identification and assessment and treatment of pain and other
151 problems, physical, psychosocial, and spiritual”.(1, 13) SHS 2.0 adopts the consensus-
152 based definition spearheaded by the IAHPIC that was initiated as one of the
153 recommendations of the Commission report and engaged a group of global
154 stakeholders from low, middle, and high-income countries. Specifically, “palliative
155 care is the active holistic care of individuals across all ages with serious health-related
156 suffering due to severe illness and especially of those near the end of life. It aims to
157 improve the quality of life of patients, their families, and their caregivers.”(12)

158 The SHS burden is presented both as the number of people experiencing SHS due
159 to life-limiting or life-threatening conditions and as the number of symptom-days of
160 SHS experienced. Individuals experiencing SHS are distinguished as either decedents
161 or non-decedents and the conditions, multipliers, and estimates in each differ.
162 Decedents are defined as individuals who died within the year of calculation and are
163 thus captured in the mortality database. Non-decedents are individuals who did not
164 die within the year of calculation and are thus captured in the prevalence database.
165 Non-decedent categories of SHS include conditions 1) that may have been cured but
166 from which SHS persists; 2) from which patients recover but that nonetheless caused
167 SHS; 3) with survival with chronic severe disability and with SHS symptoms; and 4)
168 have a slowly progressive course. Symptom-days are defined as the number of days
169 decedents and non-decedents lived with any symptoms and are calculated for each
170 symptom and aggregated to measure total palliative care need. The latter is key to

171 analyzing the response to SHS, for example in DOME for specific symptoms such as
172 pain or dyspnea.

173

174 **General considerations in the selection processes**

175 The selection of conditions, development of multipliers, and calculation of the
176 number of people and days of SHS was informed by a literature search, individual and
177 group expert discussions, and Delphi processes with online surveys for SHS 1.0 as
178 described in the Appendix to the Commission report. Expert panel(s) of palliative care
179 clinicians with experience providing clinical care in different parts of the world,
180 especially in LMICs were engaged in the process.

181 To estimate symptoms and symptom duration (days of SHS), as part of the work
182 of the Commission and SHS1.0, experts were asked to consider a typical patient with
183 each of the conditions and based on their daily experience, to generate an estimate of
184 the prevalence and duration of each symptom. During the expert consultation stage,
185 including focus group discussions and semi-structured interviews, results from the
186 literature review were presented. Experts were asked to provide responses and
187 feedback based on their work experiences even when those experiences were contrary
188 to the evidence presented to them. Either individually or in groups, all data and
189 estimates were vetted, considering assumptions and limitations or gaps to ensure that
190 all relevant aspects or scenarios are reasonably accounted for when possible. It is
191 expected that these data will serve to provide content validity for estimation of the
192 global burden of remediable suffering.(14) See appendix table 1 for a full list of the
193 experts' consensus building practices undertaken by the LC.

194 Finally, the Delphi method for consensus-building also was used to determine the
195 duration (average number of days requiring palliative care) for which palliative care
196 was needed for each of the conditions included in the database.(15) Experts were
197 purposively sampled and were considered to be 'informed individuals'(16) and
198 'specialists'(17) within the field of palliative care, in this case palliative care.(18)
199 Both rounds of the Delphi requested 18 palliative care experts living in LMICs to
200 estimate the number of days of palliative care that would be required for a patient
201 with each of the given conditions. The responses from the first round were pooled to
202 identify a group average range and standard deviation for each condition. The second
203 round of the Delphi presented respondents with the average range of days of palliative
204 care with confidence intervals for each parameter. Experts were asked to respond
205 again to the same questions based on knowledge of the group's prior responses. The
206 response rate for round one was 83% and for round two was 27%. Results from each
207 round are presented in Tables 2. See appendix table 2 for the results from the rounds 1
208 and 2 of the Delphi study. Due to limited resources, estimation for symptom-days is
209 only available from the Lancet Commission (SHS1.0) and was not updated for SHS
210 2.0.

211

212 *Taking children in account in SHS 2.0*

213 The initial SHS database from the Commission work did not differentiate the SHS
214 burden experienced by adults and children. Hence for SHS 2.0 and in collaboration

215 with and under the leadership of the International Children’s Palliative Care Network
216 (ICPCN) with the engagement of IAHP and WHPCA, an additional expert panel
217 was convened for SHS 2.0 comprised of 8 pediatric palliative care specialists from
218 both high-income and low- and middle-income settings around the world. Literature
219 review and analysis,(19) an online survey, two virtual meetings each lasting at least
220 90 minutes, and various internal discussions were conducted to differentiate the
221 calculation of palliative care needs for children and adults in select conditions.

222

223 *Time-series analysis*

224 A major improvement for SHS 2.0 is the time-series analysis to incorporate the
225 sensitivity of SHS to changes in disease trajectories, changes in pathogens, emergence
226 of new diseases, and with the evolution of and advancements in medical technologies
227 to address the burden of disease, each of which impacts the SHS burden. This gap was
228 identified through the incorporation of time series mortality and prevalence data to
229 analyze historical trends in the SHS burden. Data for 1990, 2000, 2010 and 2019 are
230 presented in the updated calculations. Those years were selected to represent the
231 earliest obtainable evidence, and data points every 10 years, and 2019 was selected as
232 the most recent year since it was the most updated year of data at the time of the
233 commencement of this analysis. The need to account for endogenous variables was
234 particularly evident for people living with human immunodeficiency viruses
235 (PLWHIV), as well as patients living with tuberculosis, cancer, or cerebrovascular
236 disease, and for children.

237

238 *Switching from WHO’s Global Health Estimates (GHE) to IHME’s Global Burden of* 239 *Diseases (GBD) database*

240 The Lancet Commission estimated the SHS burden in the most recent year of
241 available data at the time (2015) and using WHO’s global mortality database, Global
242 Health Estimates (GHE). However, due to the lack of prevalence data in GHE, non-
243 decedents were computed using fixed survivor-to-deaths ratios generated from global
244 disease-specific reports. This assumed that all countries experience the global average
245 survivor-to-deaths ratio for all conditions with non-decedents categories, not
246 accounting for country-level variation in the epidemiological profile of survivors and
247 limiting the applicability of country-specific analyses.

248 SHS 2.0 was improved along several dimensions by using the GBD database
249 released by the Institute for Health Metrics and Evaluation (IHME). Firstly, the GBD
250 includes country-specific data on mortality and prevalence. The prevalence data
251 strengthens the calculation of non-decedents with SHS. In addition, GBD data date
252 back to 1990, permitting the calculation of the burden of SHS over three decades.
253 Further, the Lancet Commission report defined children as being 0-15 years of age as
254 more disaggregated data was not available. For SHS 2.0, children are defined as 0–19-
255 year-olds to be consistent with other key publications on children’s palliative care
256 need around the world using the GBD data break-down of age groups.(19)

257

Several other global databases have also been used for SHS 2.0 in order to

258 compile better, country- and disease-specific mortality or prevalence data. Specifically,
259 the UNAIDS database for ART coverage(20) and the International Agency for
260 Research on Cancer (IARC)(21) for data on cancer patients by years of diagnosis.

261

262 **Selection of SHS-associated conditions**

263 The first step in estimating the SHS burden was to identify the health conditions
264 that most commonly cause SHS from the ICD-10 classification list that require
265 palliative care at the end-of-life due to life-threatening conditions or living with a life-
266 limiting condition (SHS 1.0). The global SHS 2.0 database includes 21 conditions,
267 and these are presented in Table 1 with their corresponding ICD-10 codes and GBD
268 codes. **Table 1: 21 conditions included in the global SHS database in ICD-10 codes
269 and GBD disease codes** All 21 groups of conditions include decedent categories,
270 considering that at least a proportion of people dying from those conditions suffer
271 from serious health-related suffering. In addition, non-decedent categories of SHS are
272 included for some of the 21 conditions that: may have been cured but from which
273 SHS persists (drug-resistant tuberculosis, some hemorrhagic fevers such as Ebola,
274 some malignancies, some inflammatory diseases of the central nervous system); from
275 which patients recover but that caused SHS (serious injuries, renal failures, preterm
276 birth complications and birth trauma); with survival with chronic severe disability and
277 with SHS symptoms (cerebrovascular disease, leukemia, congenital malformations,
278 injury, birth trauma, human immunodeficiency viruses / acquired immunodeficiency
279 syndrome (HIV/AIDS), some musculoskeletal disorders, liver diseases); and, have a
280 slowly progressive course (malignancies, dementia, Parkinson's disease, multiple
281 sclerosis, type-1 diabetes, thalassemia, and sickle cell disorders).

282 In the original Lancet Commission report, the non-decedents category for 11
283 conditions were considered. In SHS 2.0, non-decedents categories for four more
284 conditions were added and differentiating factors were used that are important to
285 estimating suffering patterns. **Panel 1** provides a detailed description of how
286 decedents and non-decedents in need of palliative care are estimated for each
287 condition as well as key literature and extra databases used to calculate the decedents
288 and non-decedents with SHS. Conditions are ranked using the alphabetical order of
289 their ICD-10 codes.

290 As the result of the exercise to estimate palliative care needs for children, there
291 was consensus that the following conditions be added due to their substantive
292 contribution to SHS among children for both decedents and non-decedents: 1)
293 diabetes mellitus, 2) sickle cell disorders, 3) thalassemia, and the following conditions
294 for non-decedents categories of: 1) leukemia, 2) liver diseases, 3) chronic kidney
295 diseases, 4) neonatal preterm birth and birth trauma. Hence, while SHS 1.0 included
296 20 conditions, SHS 2.0 includes 21 groups of conditions with the addition of
297 endocrine, metabolic, blood, and immune disorders which include diabetes mellitus,
298 sickle cell disorders, and thalassemia for decedents and non-decedents.

299 The review of the case of diabetes in children prompted an overall review of the
300 included conditions. For diabetes mellitus in adults, deaths from sequelae are
301 attributed to the proximal cause and hence considered captured in other conditions

302 included in the SHS database and specifically, cerebrovascular disease,
303 cardiomyopathy and/or heart failure, chronic ischemic heart disease, renal failure, and
304 atherosclerosis. Because deaths from diabetic ketoacidosis or hyperglycemic
305 hyperosmotic non-ketotic syndrome typically result in death so rapidly that there is no
306 time to institute quality palliative care services, these conditions are not included. In
307 the pediatric population, diabetes mellitus is added due to the concerns over pain and
308 suffering caused by type-1 diabetes even in the absence of organ complications.

309 Efforts to alleviate SHS experienced by a newborn, the assurance of the
310 newborn's comfort and that of distraught parents should accompany aggressive life-
311 sustaining treatments if they are to reasonably provide more benefit than burden.
312 Palliative care must also be available as an alternative to potentially harmful life-
313 sustaining interventions when a newborn is moribund. Hence, in both SHS 1.0 and
314 SHS 2.0, extremely premature and very low birth weight newborns whose survival is
315 unlikely, and babies born with severe hypoxic ischemic encephalopathy or congenital
316 anomalies not compatible with life are included in the list of SHS conditions.

317 In both SHS 1.0 and SHS 2.0, leukemia is considered a separate condition than the
318 rest of the malignancies due to its distinctive patients' demographics and suffering
319 patterns.

320

321 **Selection of types or symptoms of suffering**

322 Patients' suffering varies by type, severity, and duration and a clinically, economically,
323 and strategically useful measure of SHS requires estimation of not only the number of
324 patients who suffer, but also the type of suffering and duration of suffering. Therefore,
325 overarching categories of suffering were identified in SHS1.0 and then within those
326 categories, the types or symptoms were associated with each condition.

327 Palliative care literature typically divides suffering into four categories – physical,
328 psychological, social, and spiritual – to encompass the full spectrum of human
329 suffering. While the Lancet Commission accepted and adopted all four categories as
330 SHS, the focus was on estimating the prevalence and duration of only physical and
331 psychological categories of suffering and corresponding symptoms. The empirical
332 evidence from published literature or expertise to produce reasonable estimates of the
333 prevalence and duration of each type of social and spiritual suffering were not
334 sufficient.

335 To estimate SHS as precisely as possible, the Commission's expert group
336 identified the most common symptoms of physical and psychological suffering, and
337 then estimated the prevalence and duration of each type of suffering associated with
338 each condition or its treatment. Through literature review and evidence-informed
339 expert consensus building exercises, physical and psychological types of suffering
340 (symptoms), their frequencies and durations for each condition were identified as part
341 of Commission work. See **Figure 1** for details. Specifically, the types of physical
342 suffering include: moderate or severe pain, mild pain, weakness, fatigue, shortness of
343 breath, nausea and vomiting, constipation, diarrhea, dry mouth, itching, wounds and
344 bleeding. The types of psychological suffering identified include: – anxiety and worry,
345 depressed mood, delirium or confusion, and dementia with disorientation, agitation, or

346 memory loss. Table 2 summarizes the duration of each type of physical and
347 psychological suffering and appendix table 3 lists the results from the literature
348 review on prevalence of the most commonly reported type of physical suffering
349 among patients with serious, complex, or life-limiting health problem. [Table 2: The
350 estimates of duration of each type of physical and psychological suffering by
351 condition]

352 Most published data on symptom prevalence comes from high or upper-middle
353 income countries where both disease-modifying and palliative treatments are most
354 accessible. Furthermore, most of the literature either focused on physical and
355 psychological symptoms among a single group of patients (such as cancer), or a single
356 symptom (such as pain) in patients with various conditions. Data, mostly from high
357 income countries, indicates that well over 50% of people who die of or live with
358 malignant neoplasms and AIDS experience pain, and that pain is also common among
359 those who live with heart disease, chronic obstructive pulmonary disease (COPD),
360 renal failure, neurologic disease and dementia.(22, 23) Dyspnea (shortness of breath)
361 is especially common among people who live with COPD and heart failure and only
362 slightly less common among those who live with malignant neoplasms and AIDS.(24)
363 Depressed mood and anxiety are widespread among patients with a variety of
364 advanced life-threatening illnesses including metastatic cancer and trauma.(25, 26)
365 There are fewer studies among patients with most other serious, complex, or life-
366 limiting health problems.

367 Of note, dementia appears both in the list of conditions (Alzheimer's disease and
368 other primary dementias) and as a symptom of other conditions (HIV/AIDS,
369 cerebrovascular disease, and other neurologic conditions). The term dementia is
370 therefore used in two ways, and the distinction in use of each instance is required.

371

372 **Identifying multipliers for each condition**

373 The next step in measuring SHS was to determine the proportion of people with each
374 condition who experience SHS. These are called multipliers. Multipliers are
375 mathematical factors that estimate number of people dying or living with SHS based
376 on different data sources. They reflect different strategies applied in the estimation
377 and are provided separately for decedents and non-decedents. For decedents, the
378 multipliers are always a percentage between 0 and 100%, to be applied to total deaths.
379 For non-decedents, the multipliers take one of the three different forms: 1) a
380 percentage between 0 and 100% to be applied to total number of patients living with
381 the disease; 2) a ratio that can go over 100% to be applied to total deaths; or 3) a ratio
382 that can go over 100% to be applied to total decedents in need of palliative care. See
383 table 4 with more details.

384 To identify the proportion of people with each condition who experience SHS for
385 the different conditions and sub-conditions and therefore identify appropriate
386 multipliers to use for each, an extensive literature review was conducted for both
387 decedents and non-decedents. Empirical evidence of symptom burden for some
388 conditions was identified, but most studies were conducted in high-income settings.

389 Evidence identified from the literature could not directly be used as multipliers since
390 much of it was focused on patients in a certain stage of care whilst the SHS
391 calculation requires multipliers for both people who die within that year – decedents-
392 and another for people who live with a condition – non-decedents. As a result,
393 empirical evidence on percentage of patients with each condition experiencing SHS
394 from the literature review were summarized and presented as the basis of discussion
395 in various expert consensus building exercises. When estimating the SHS burden of
396 non-decedents, experts were asked to consider the SHS burden of an “average”
397 patient for each condition among all patients living with that condition who are not in
398 their last year of life.

399

400 Because SHS 2.0 incorporates analysis across a number of years, it was possible
401 to implement improvements to the multipliers for HIV and tuberculosis (TB). SHS
402 stemming from HIV among non-decedents was differentiated between individuals
403 undergoing anti-retroviral treatment (ART) from those who are not, reflecting how the
404 advent of ART and increased access to such treatment revolutionized care for
405 PLWHIV and in turn, SHS associated with HIV. Furthermore, extensively drug-
406 resistant TB (XDR-TB) is differentiated from multidrug-resistant TB (MDR-TB),
407 because antimicrobial resistance and the rise of XDR TB pose major challenges to
408 treatment of tuberculosis which is different from MDR-TB.

409 For cancer, SHS2.0 also incorporates data across additional years for the
410 estimation of multipliers. In SHS2.0, unlike for the Commission report, five-year
411 survival data were used to estimate non-decedent SHS for malignant neoplasms and
412 leukemia. The GBD data reports only overall survival and does not further
413 disaggregate by years since diagnosis. Hence, the GBD data were adjusted based on
414 the prevalence and mortality data extracted from the Global Cancer Observatory
415 (GLOBOCAN) 2018 (See **Panel 1** and Table 3) that report cancer survivorship for 1,3
416 and 5 years from diagnosis. **Table 3. Multipliers of cancer survivors at 1, 2, 3, 4, and**
417 **5 years of diagnosis** A country-specific linearly interpolated trend was applied to
418 estimate prevalence for year 2 and 4 post diagnosis. The approximation of survival
419 was estimated as the ratio between the total deaths and the prevalence in the same
420 period. Lastly, to estimate non-decedent burden for 1990, 2000 and 2010 given that
421 information on 5-year prevalence and survival is not available by year since diagnosis,
422 the GLOBOCAN 2018 data are adjusted using country-income specific quintile
423 distribution data on percentages of all cancer survivors being with each year of
424 diagnosis. (see Table 4 for detail). **Table 4. Percentiles used to impute number cancer**
425 **survivors at 1, 2, 3, 4, and 5 years of diagnosis in historical years**

426 Cerebrovascular diseases constitute a major component of overall SHS, yet its
427 non-decedent category was a limitation in SHS1.0. For SHS2.0, non-decedent SHS
428 was calculated for patients living in the year prior to their last year of life, assuming
429 that most patients who live for extended periods with this condition do not experience
430 SHS (as the condition is largely asymptomatic until it becomes serious enough to
431 result in death). Still, data are scarce on the proportion of cerebrovascular disease
432 patients in the final years of life and hence with SHS. An estimate of the proportion of

433 patients who are diagnosed and die in the same year was developed based on a
434 literature search focusing on differences by country income level and this was applied
435 to two years of cerebrovascular disease mortality. (see Tables 5, 6 and appendix table
436 4). [Table 5: Estimation model used in calculation of cerebrovascular disease patients
437 living with SHS – part 1] [Table 6: Estimation model used in calculation of
438 cerebrovascular disease patients living with SHS – part 2] Because data were not
439 available on the number of deaths per year of patients diagnosed in the last year, a
440 literature search was carried out on the survival of these patients in countries by
441 income level. In other words, the calculation factored in the percentage of newly
442 diagnosed patients that would die within one year as the percentage among all deaths
443 that would occur due to newly diagnosed patients. As literature covering all income
444 groups was not available in all years of interest, i.e. 1990, 2000, 2010 and 2019,
445 missing years and income groups were imputed to the nearest income group and/or to
446 all the year (Tables 8 and 9). The new method limited the estimation of SHS only to
447 patients within the last 1-2 years of their life, since most patients living with
448 cerebrovascular disease can spend years living without SHS. While this method gives
449 us a more realistic estimate of the suffering endured by cerebrovascular disease
450 patients, there is little literature to report an estimate of the percentage of total
451 cerebrovascular disease patients who are in the last 1-2 years of their life (Table 10).
452 Therefore, we applied a series of assumptions plus a limited compilation of data from
453 our literature review to construct the matrix of percentages of cerebrovascular disease
454 patients living within the last 1-2 years of their life by income group, to 1990, 2000,
455 2010, and 2019. These assumptions are limitations of this study, given the varying
456 strength of the underlying data.

457 Table 7 presents the multipliers used to calculate SHS for all 21 conditions,
458 separating decedents and non-decedents. [Table 7. Multipliers used to calculate SHS
459 burden for 21 conditions]

460
461

462 **III. Data limitations and Future Iterations**

463 The measurement of the global burden of SHS presented in the Lancet Commission
464 report set a precedent and the update to SHS2.0 is an important move forward in
465 measuring the number of people in need of palliative care. However, there are
466 important limitations and there remains work to refine the estimation strategy and
467 hence the estimates.

468

469 **Data limitations**

470 First, although a literature review was conducted by condition and symptoms, due to a
471 dearth of reliable empirical data on the types, prevalence, and duration of suffering
472 caused by each SHS associated health condition, both SHS1.0 and 2.0 rely heavily on
473 expert opinion. Moreover, research on palliative care has so far concentrated on
474 Europe and the United States accounting for over 90% of all publications on palliative

475 care but only 15% of the global population. The fact that 85% of the global population
476 produced only 6.5% research publications points to the glaring lack of information on
477 the elements of suffering for the majority of people in the world.(27)

478 Further, the expert groups are relatively small reflecting limitations in available
479 funding to develop the field of SHS. This makes it especially difficult to develop
480 either disease, region, or country income-specific estimates. The reliance on
481 identifying an “average” patient limits the possibility of exploring regional, cultural or
482 other differences, as well as the effect of providing differential levels of palliative care.
483 The next step in the SHS work is to undertake disease-specific expert panels to refine
484 estimates of people with SHS and especially symptoms and symptom days. This is the
485 focus of research planned for SHS 3.0 and has been piloted for breast cancer and will
486 soon commence on HIV.

487 Second, there are conditions which generate SHS but are not included in the
488 analysis to-date due to limited scope. For example, chronic paranoid schizophrenia
489 and other severe chronic psychiatric disorders generate severe suffering but are not
490 included in the methods presented here. Another important example is people living in
491 the context of humanitarian crisis,(28) including armed conflict(29) but also climate
492 emergencies, communicable disease outbreaks or those under threat of political,
493 sexual, or ethnic violence who suffer from various types of physical and
494 psychological suffering.

495 Similarly, our work to date extends to 2019. Estimating the shorter-term SHS that
496 was associated with the coronavirus disease 2019 (COVID-19) pandemic, and the
497 longer-term sequelae for those who suffered the disease should be a key next step in
498 the analysis. This should include the suffering associated with bereavement and the
499 lack of access to palliative care support for caregivers, family members and the
500 community during COVID-19 lockdowns. The wealth of data and publications on the
501 pandemic will make this analysis more feasible.

502 Family caregivers who experience various kinds of physical, psychological,
503 social, and spiritual suffering as a result of their care work are not included in the
504 estimates. While methods to estimate the types, prevalence, or duration of physical,
505 psychological, social, or spiritual suffering of the main family or informal caregiver
506 have not been within the scope of SHS calculations to-date, this is an important area
507 of future SHS methodological development. Family caregivers typically provide
508 many hours of daily care to patients with serious, chronic, complex, or life-limiting
509 health problems and in many health care settings, especially in LMICs, where they
510 must remain with the patient when admitted to the hospital. Across the world,
511 caregiving work at home and in the communities is predominantly provided by
512 women, and often uncompensated or undercompensated.(30) It has been shown that
513 caregiving can itself represent a source of suffering.(31, 32) Family caregivers may
514 have their own need for palliative care and support in managing bereavement.

515 Expert opinion provides important information, but a patient-centered approach
516 needs to be included in future work on SHS. Confirmatory research on symptom
517 prevalence and severity with patient- and caregiver- reported real-life data must

518 complement future work. This limitation applies to the symptoms as well as many
519 dimensions of suffering that are important for patients, caregivers, and practitioners.
520 The expert panel identified 11 physical and 4 psychological symptoms, but this is far
521 from an exhaustive list of all possible physical and psychological symptoms patients
522 can experience. Social or spiritual suffering is also not estimated despite being a
523 source of grave concern due to the impact on overall quality of life.(33, 34) In the
524 context of paucity of resources, of poorly organized healthcare systems and of
525 marginalization of large chunks of the population, the impact on the burden of
526 suffering is likely to be considerable.

527 Further, the quantity of suffering is estimated only in terms of number of people
528 who died from or lived with SHS (SHS 1.0 and SHS 2.0), or the number of symptom
529 days they each experience (SHS 1.0). This approach neglects the intensity or
530 tolerability of suffering experienced. In SHS 3.0, opportunities for understanding the
531 scope and intensity of social and spiritual suffering for patients in need of palliative
532 care will be explored. Gathering patient- and caregiver reported data is the optimal
533 solution to fill in these gaps and should be a priority for donors and foundations
534 interested in improving access to palliative care and achieving the Sustainable
535 Development Goals (SDGs). To date, only a few pilot and exploratory surveys have
536 been undertaken.(35, 36)

537 Another important area for future work is to determine to what extent suffering
538 can be alleviated with existing practices and techniques at various resource-levels.
539 This also means that the multipliers – percentage of deaths or survivors in need of
540 palliative care by condition – are time-period specific and should change over time
541 based on previously noted endogenous variables, including the change in disease
542 trajectories and their suffering patterns, as health care technologies and systems
543 evolve.

544 Last but not least, our work looks at one side of the issue: the demand side. It is
545 equally important, if not more, to measure how much of the need for palliative care is
546 fulfilled, by whom, in what quality, and where. Combined with analysis of the actual
547 provision of palliative care, we will be able to identify gaps and provide more tailored
548 policy recommendations.

549

550 **Future Iterations**

551 The methods described in this paper are pioneering in the field. However, our
552 exploration has only expanded our vision of the bigger, unknown world, leaving more
553 gaps to be filled with future research. Even the more detailed estimate of “symptom-
554 days” – as opposed to number of people – has limitations as a measure of the burden
555 of SHS experienced by patients in the absence of a method to weigh the tolerability or
556 intensity of each symptom. Specifically, the number of days is calculated for each
557 symptom using the available information on symptom prevalences and duration for
558 each condition. Simple aggregation of days with each symptom may lead to
559 overestimation from double counting, as many patients with advanced disease will
560 suffer from more than one symptom at the same time. As such, the Commission report
561 presented two aggregate indicators to evaluate the total symptom burden: 1) the “at

562 least” SHS-days, which equals the symptom-days from the single most prevalent
563 symptom, in most case, pain, of each condition, and 2) the total symptom days should
564 is the sum total of all symptoms. The actual days of suffering experienced by people
565 with SHS should be a number between these two bounds. Ongoing refinement of the
566 calculation of the number of days of SHS experienced by the population in a given
567 year is a core area for SHS 3.0. Moreover, and as described, it is important to note that
568 the calculation of the number of days of SHS is derived from the calculation of the
569 number of people with SHS, not the other way around. As a contribution to
570 measurement of burden, several “summary indicators” or ways to characterize the
571 suffering experienced by patients were developed. Panel 2 presents these secondary
572 indicators that were constructed for the Lancet Commission report. Another
573 dimension that has not been measured to date is to match SHS to an estimate of
574 palliative care need assessment such as the estimated number of required “palliative
575 care visit-days” – the number of days in which a palliative care provider should see
576 the patient, family or caregiver. Symptom days measures only the days during which
577 the symptom(s) persist(s), regardless of whether a visit by or with a palliative care
578 provider is needed. Severe, refractory, or poorly tolerated symptoms may require daily
579 visits while well-controlled symptoms may require a visit only every 2 to 4 weeks.
580 Indeed, provision of effective palliative care can, and should, reduce the number of
581 symptom days as well as the severity of the symptoms. In doing this, palliative care
582 reduces the SHS burden. This remains an area for future discussion and analysis.

583

584 **IV. Discussion**

585 This paper is designed to serve as a reference document for calculating SHS.
586 Detailing the methodology is also intended to promote transparency in ongoing efforts
587 to measure the burden of SHS and to promote wider discourse on the assessment of
588 SHS burden that will inform future iterations of SHS measurement and data
589 strengthening. Improving the science of the measurement of SHS will support policies
590 that increase palliative care access and infrastructure as a component of UHC and
591 improve population health.

592 The estimates generated from this methodology can be used independently or can
593 serve as an input to the development of composite metrics that compare interventions
594 in terms of suffering averted. Researchers can apply the methods presented using
595 country-specific data (i.e. not GBD estimates, which are used here) to generate
596 national and sub-national calculations of SHS.(37, 38) Researchers can also use our
597 methods to project trends and examine the future scale of the burden of SHS overall
598 or by condition.(39) The SHS burden data is also a necessary input to calculating the
599 cost of an essential package of palliative care services, as introduced by the Lancet
600 Commission.(37)

601 Data on SHS burden is critical to evaluating health status and as such, for the
602 monitoring and evaluation of health systems performance to achieving universal
603 access to palliative care.(40) The number of people with SHS (calculated without a
604 threshold or cutoff in terms of days of SHS experienced) provides a specific insight
605 on palliative care need – an estimated number of patients that need access to palliative

606 care services. Policymakers and practitioners can be guided by the magnitude of SHS
 607 within their countries, the distribution of SHS across conditions, age ranges, and
 608 geographical locations, and the corresponding need for palliative care, so that they
 609 may examine it against the availability of palliative care service. SHS data are hence
 610 useful in assessing the need and efficacy of approaches to health system strengthening
 611 and UHC, health reforms or across health insurance schemes. Further, the evidence on
 612 need can further the argument for adoption of the packages of palliative care services,
 613 as was begun with work on the essential package by the Lancet Commission with the
 614 Disease Control Priorities (DCP)-3.(11) The number of days of SHS is therefore also
 615 essential and particularly to measure how need must translate into a health system
 616 response such as through an essential package of palliative care services.

617 Acknowledging this and the previously presented limitations, this paper provides
 618 a starting point for further scientific inquiry and consensus-building. The methods
 619 described in this paper pave the way forward for future research that examines both

620 the demand side—suffering patterns—and the supply side—ways to address them—for
 621 people worldwide. With the methodology to measure SHS, as established by this
 622 paper, what’s needed next are better tools to measure the responses to relief, building
 623 on existing efforts such as DOME. The next step and complement to this paper is
 624 another on DOME that begins to identify access to one facet of palliative care – pain
 625 relief medicine, plus a paper looking specifically at SHS in children. Matching
 626 DOME and SHS provides an indicator of health system performance and progress
 627 over time in delivering palliative care and reducing the unmet burden of SHS.

628 Estimating the burden of SHS should be a continual endeavor to incorporate
 629 scientific, societal, economic, and health care system change into the quest to reduce
 630 suffering and improve population health. This must include monitoring advances, but
 631 also the challenges that pose a risk to human health and quality of life, including
 632 climate change, war, and humanitarian crises. The measurement of serious health-
 633 related suffering can serve as a basis for promoting people-centered health systems
 634 and analyzing progress toward SDG3 and for future iterations of global health goals
 635 and the quest for UHC. It also has the potential to change the focus of today’s
 636 healthcare system from diseases alone to suffering. The tools shared in this paper and
 637 its contributions toward better conceptualization and measurement of the burden and
 638 alleviation of SHS should catalyze this work.

639

640 V. Acronyms

Acronyms	Full names
AIDS	Acquired immunodeficiency syndrome
ART	Anti-retroviral treatment
COPD	Chronic obstructive pulmonary disease
COVID-19	Coronavirus disease 2019
DALYs	Disability adjusted life years
DCP	Disease control priorities
DOME	Distributed opioid morphine equivalent
GBD	Global Burden of Diseases

GHE	Global Health Estimates
GLOBOCAN	Global Cancer Observatory
HIV	Human immunodeficiency viruses
IAHPC	International Association for Hospice and Palliative Care
ICD	International Classification of Diseases
ICPCN	International Children’s Palliative Care Network
IHME	Institute for Health Metrics and Evaluation
LMICs	Low- and middle-income countries
MDR-TB	Multidrug-resistant tuberculosis
PLWHIV	People Living with HIVs
QALYs	Quality-adjusted life years
SDG	Sustainable Development Goal
SHS	Serious health-related suffering
TB	Tuberculosis
UHC	Universal health coverage
UMIA	University of Miami Institute for Advanced Study of the Americas
WHO	World Health Organization
WHPCA	Worldwide Hospice Palliative Care Alliance
XDR-TB	Extensively drug-resistant tuberculosis

641

642

643 **VI. Acknowledgments**

644 The authors are grateful to the Lancet Commission on Palliative Care and Pain Relief
645 Study Group and acknowledged contributors in the Lancet Commission report for
646 their inputs to an earlier iteration of this work. We would also like to thank all
647 palliative care specialists who contributed to experts panels and related Delphi
648 processes for the Lancet Commission and subsequent pediatric specific expert reviews
649 for SHS 2.0. We thank Kathy Foley for her various inputs to the Lancet Commission
650 and beyond to help make this work a reality. Finally, we thank all individuals who
651 have supported this work in different ways and at varying points.

652

653 **VII. Conflicts of Interest**

654 XK and AB report consulting fees from the University of Miami Institute for the
655 Advanced Study of the Americas for part of the submitted work and consulting fees
656 through a research grant from the Medical Research Council to the University of
657 Edinburgh for work related to palliative care outside the submitted work. FMK
658 reports research grant funding to the University of Miami from the U.S. Cancer Pain
659 Relief for part of the submitted work and from ABC Global Alliance outside the
660 submitted work; research grant funding from the Medical Research Council to the
661 University of Miami and FUNSALUD (Mexican Health Foundation) for work related
662 to palliative care outside the submitted work; research grant funding to Tómatelo a

663 Pecho, A.C. from Breast Cancer Now related to palliative care outside the submitted
 664 work; research grant funding to Tómatelo a Pecho, A.C. outside submitted work from
 665 Merck Sharp & Dohme, Avon Cosmetics; research grant funding to the University of
 666 Miami outside submitted work from Merck KGaA/EMD Serono; and personal fees
 667 from Merck KGaA/EMD Serono and Tecnológico de Monterrey. FMK is on the
 668 board of the IAHPC, Founding President of Tómatelo a Pecho, A.C, and Senior
 669 Economist for FUNSALUD. All other authors declare no competing interests.

670

671 **VIII. Funding**

672 We acknowledge support from the University of Miami and U.S. Cancer Pain Relief
 673 for this work.

674

675 **Panel 1:** Core assumptions for estimating decedents and non-decedents in need of
 676 palliative care

Hemorrhagic Fever
<p>Decedents</p> <ul style="list-style-type: none"> • 100% of deaths from hemorrhagic fever, which is about 5% of other infectious diseases. <p>Non-Decedents</p> <ul style="list-style-type: none"> • Approximately the same number of patients who recover from the disease as those who die from it.(41-45)
Tuberculosis (TB)
<p>Decedents</p> <ul style="list-style-type: none"> • 100% of patients who die from MDR-TB.(46-48) MDR-TB deaths estimates were provided by the GBD database separately from the drug susceptible TB deaths, so we no longer need to estimate the deaths from MDR-TB using the proportion calculated from global reports as we did for SHS 1.0. • 90% of drug-susceptible TB deaths. Regular TB deaths were calculated using total TB deaths minus MDR-TB deaths as described above. <p>Non-Decedents</p> <ul style="list-style-type: none"> • given the natural history of TB as a condition of relatively short duration as compared to other SHS conditions, especially in the case of MDR-TB and XDR-TB, we estimated the number of MDR and XDR TB patients living with SHS in any given year to be the incidence number minus the deaths number. Subsequently, the non-decedents in need of palliative care for tuberculosis was estimated to be 100% of XDR-TB patients plus 50% of MDR-TB patients living with SHS: Total TB-nondec = 100% * XDR-TB (incidence-deaths) + 50% * MDR-TB (incidence-deaths)
HIV/AIDS
<p>Decedents</p> <ul style="list-style-type: none"> • 100% of people who die from HIV/AIDs.(24, 49-52) <p>Non-Decedents Not on Treatment</p> <ul style="list-style-type: none"> • 50% of people living with HIV (PLHIV) (non-decedents in 2015) required some type of palliative care.(53-56) <p>Non-Decedents on Treatment</p> <ul style="list-style-type: none"> • For PLHIV who are on ART, the percentage with SHS was estimated at approximately 15%, much lower than those without ART. GBD country-specific prevalence of HIV/AIDs was used to estimate PLHIV. Data on percentage of HIV patients on anti-retroviral therapy (ART) (ART coverage) was obtained from the World Bank Group based on UNAIDS estimates, and average levels of ART coverage for each income group were calculated using country-specific data available for each time point. Actual country income group classifications for each respective year were utilized to generate ART coverage averages by income group. We used the below assumption: Number of HIV patients living with SHS = [HIV prevalence * proportion of HIV patients on ART * 15%] + [HIV prevalence * (1 - proportion of HIV patients on ART) * 50%]

- Due to the timeline of the advent of antiretroviral (ARV) drugs and combination therapy, widespread introduction of ARVs after the surge of HIV prevalence, time delay in rollout of ARVs in low-income countries as compared to lower-middle, upper-middle, and high-income countries and data availability on ART coverage, ARV adjustment was only made for the years of 2000 (all income groups except low-income countries), 2010, and 2019. For 1990, based on unavailability of ART or ART coverage at 0%, the number of HIV patients with SHS equals total prevalence multiplied by 50%.

Malignant neoplasms (except leukemia)

Decedents

- 90% of patients who die from malignant neoplasms (except leukemia).(24, 57-59)

Non-Decedents

- According to International Agency for Research on Cancer (IARC), there were 32.6 million people older than 15 who were alive with a cancer diagnosis within the previous 5 years in 2012.(60) Shi, et al.,(61) report that 28% of people who survive one year with cancer have a “high-symptom burden.” We assumed that people with a high-symptom burden need palliative care. Zucca, et al.(62), report that few people who survive cancer for more than five years have symptoms that require palliative care unless they have a recurrence or another disease. Data on the percentage of the 32.6 million non-decedents who survive 1, 2, 3, 4, and 5 years, and on the need for palliative care at years 2, 3, 4, or 5 was unavailable. The International Agency for Research on Cancer (IARC) has data on survivorship from selected cancers in selected countries,(60) but in the absence of global data, we estimated the number of non-decedents by year since their cancer diagnosis and the percentage of these non-decedents who need palliative by year since cancer diagnosis (**Table 2**). IHME prevalence data on malignant neoplasms includes all persons with a cancer diagnosis, regardless of their years, so we decided not to use their cancer prevalence data. The IARC has data on survivorship from selected cancers in selected countries within 5 years of diagnosis,(60) but only for 1, 3 and 5 years of diagnosis. Thus, IARC data was used, and a linear distribution was assumed to impute for patients with 2 and 4 years of diagnosis respectively. **Table 2. Multipliers cancer survivors at 1, 2, 3, 4, and 5 years of diagnosis**
- Since cancer mortality data in GLOBOCAN is not available for the previous four years for each country, the following was assumed: $Mort5years=Mort2018*5$
- Mort2018 corresponds to cancer mortality in 2018 (GLOBOCAN database). Countries were grouped by income level, based on World Bank 2017 classifications. Five-year survival by income group was estimated, generating the following:
 - Low income = 0.30
 - Lower-middle income=0.361
 - Upper-middle income=0.459
 - High-income=0.574
- Similarly, each income group was divided into quintiles according to its 5-year survival rate. Table 6 shows the assumptions for calculating the survival rate for each year that is not available from the GLOBOCAN database.
- Based on table 6 below, it is assumed that survival in the low-income region in 1990 is similar to what survival in the first quintile of that region is today. In 2000, the same group of low-income countries had what the first two survival quintiles for low-income countries have today; that is, 0.24. Meanwhile, in 2010 the first three quintiles correspond to 0.26. For 2017, the current distribution reported by GLOBOCAN was used. **Table 3. Percentiles used to impute number cancer survivors at 1, 2, 3, 4, and 5 years of diagnosis in historical years**

Leukemia

Decedents

- 90% of patients who die from leukemia; needs of people with leukemia are of shorter duration or lower intensity than those of people with solid tumors. An exception is some patients in HICs with chronic, difficult-to-control graft-versus-host disease. This globally unusual need was taken into consideration when estimating the duration of need among leukemia patients.

Non-Decedents

- Non-decedent category for leukemia was added for SHS 2.0 and was calculated separately for children and adults. For children, we estimate that 85% of total survivors living in low-income and lower-middle income countries, 60% of total survivors living in upper-middle income countries, and 25% of total survivors living in high-income countries are living with SHS.

Overall, that constitutes 65% of the global total survivors. The children's expert group placed particular emphasis on the burden of leukemia in low-income countries and the differentials across countries and this is reflected in the multipliers. This approach innovates on previous estimates and is an ongoing area of discussion for alignment with measuring SHS for other conditions. For adults, the calculation is the same as for other malignant neoplasms.

Dementia

Decedents

- Approximately 80% of people who die from Alzheimer's disease or other dementias in the year they die.(24, 63-65)

Non-Decedents

- Approximately 25% of these people had advanced or late dementia. Moens et al.(24) found that 40% of persons with advanced or late dementia had symptoms requiring palliative care (the need for psychological and social support for caregivers likely would yield a higher percentage of need for palliative care, but data on this need are lacking). We thus estimated that 10% (25% * 40%) of people living with dementia are experiencing SHS. The number of people living with dementia came from GBD's prevalence database.

Inflammatory disease of central neural system

Decedents

- [70% of patients who die from syphilis] + [50% of patients who die from measles] + [100% of patients who die from tetanus] + [30% of patients who die from meningitis] + [30% of patients who die from encephalitis] + [100% of patients who die of trypanosomiasis] + [90% of patients who die from rabies].

Non-Decedents

- For every two patients who die from tetanus and require palliative care, there will be one patient who survives tetanus that requires palliative care.

Extrapyramidal & movement disorders; other degenerative disease of CNS; demyelinating disease of CNS; Epilepsy; Cerebral palsy & other paralytic syndromes

Decedents

- [65% of patients who die from Parkinson's disease] + [50% of patients who die from epilepsy] + [100% of patients who die from multiple sclerosis] + [65% of patients who die from other neurological conditions].(66-78)

Non-Decedents

- **Parkinson's disease:** Advanced disease and the attendant distressing symptoms occur approximately nine years after symptoms first appear,(79) and we estimate conservatively that 25% of patients survive long enough to have advanced disease and do not die in a given year. Based on the work of Moens, et al.,(24) we estimate that 40% of these patients require palliative care. We thus estimated that 10% (25% * 40%) of people living with Parkinson's disease are experiencing SHS and thus need palliative care..
- **Multiple sclerosis (MS):** MS has a long prognosis and shortens life by only 0 – 6 years. Thus, we estimated that 5% of people with MS who do not die in a given year have end stage disease. Based on the work of Moens, et al.,(24) we estimated that 34% of these patients – about 2% of total survivors - require palliative care. The number of people living with multiple sclerosis was calculated by applying the ratio of global survivors: deaths.

Cerebrovascular diseases

Decedents

- 65% of people who die from stroke.(80-88)

Non-Decedents

- The mortality number for the next year was subtracted from the proportion of deaths expected to be within 1 year of diagnosis to approximate the number of cerebrovascular patients living with SHS. Mortality from three sub-categories of stroke, i.e., ischemic stroke, hemorrhagic stroke, and subarachnoid hemorrhage were summed, each subtracted from the proportion of deaths expected to be within the first year of diagnosis. Since actual data for the number of deaths for each year of

patients diagnosed within the last year was not available, cohort survival data from literature review were used. In other words, we used the possibility that newly diagnosed patients would die within a year as the percentage among all deaths that would be from the newly diagnosed.

- As literature that covered all income groups across all historical years of interest was not available, missing years and income groups were imputed with the closest income group and/all year. The new method limited the estimation of SHS to only patients within the last 1-2 years of their life, since the majority of patients living with cerebrovascular disease can spend years living without SHS. While this method gives us a more realistic estimation of the suffering endured by cerebrovascular disease patients, there is scarce literature to inform an estimate of the percentage of total cerebrovascular disease patients who are within the last 1-2 years of their lives. Thus, a series of assumptions plus a limited compilation of data from our literature review were applied to construct the matrix of percentages of cerebrovascular disease patients living within the last 1-2 years of their lives by income group, for 1990, 2000, 2010 and 2017. These assumptions are limitations of this study given the varying strength of the underlying data. See table 4-6 for details. [Table 4: Estimation model used in calculation of cerebrovascular disease patients living with SHS – part 1]; [Table 5: Estimation model used in calculation of cerebrovascular disease patients living with SHS – part 2]; [Table 6. List of literature review used in calculating the 5-year survival by income group and by year]

Chronic rheumatic heart disease; Cardiomyopathy & heart failure

Decedents

- [65% of patients who die from rheumatic heart disease] + [70% of patients who die from hypertensive heart disease] + [40% of patients who die from cardiomyopathy, myocarditis and endocarditis] + [30% of patients who die from Chagas disease].(24, 89-94)

Chronic ischemic heart disease

Decedents

- 5% of patients who die from ischemic heart disease.(95)

Chronic lower respiratory disease; lung disease due to external agents; interstitial lung disease; other disease of respiratory system

Decedents

- [80% of patients who die from COPD] + [50% of patients who die from other respiratory diseases except asthma].(24, 96-98)

Diseases of liver

Decedents

- [95% of patients who die from cirrhosis of liver] + [28% of patients who die from other digestive diseases].(99-103)

Non-Decedents

- There is little literature describing the suffering of the general liver patients population. We found a recent publication of patients with end-stage liver disease but the including criteria included decompensated liver diseases,(104) while the vast majority of patients living with liver disease are mild or well compensated. In another study, D'Amico et al observed that patients with decompensated cirrhosis (or end stage liver disease ESLD), this is those who have complications and who cannot access to a liver transplant, have a median survival of 2 years.(105) We thus estimated that for adults, if patients with end-stage disease may have SHS for two years before deaths, so the non-decedents number equal that of the decedents. For children, the early onset of liver diseases can cause more damage to the growing organ and thus generate more suffering. So we estimated that the number of pediatric patients living with liver diseases that cause serious health-related suffering is about 3 time that of the deaths every year.

Renal failure

Decedents

- 45% of patients who die from kidney disease.(24, 106-108)

Non-Decedents

- We couldn't find any literature on the suffering of a "typical" or "average" patients living with chronic kidney diseases. We thus took a similar approach as other conditions: we assumed an average of 3 years from onset of SHS to deaths for a "typical" or "average" patient. Thus, the number of non-decedents were calculated as twice the number of decedents with SHS. For children, the early onset of kidney diseases can cause more damage to the growing organ and thus generate more suffering. So we estimated that the number of pediatric patients living with chronic kidney

diseases that cause serious health-related suffering is about 3 times that of the deaths every year.

Low birth weight & prematurity; birth trauma

Decedents

- [75% of patients who die from preterm birth complications] + [40% of patients who die from birth asphyxia and birth trauma].(109-113)

Non-Decedents

- The non-decedent category for low birth weight and birth trauma was only added for children. We estimate that about 1% of children under 5 low birth weight survivors, 20% of children under 5 birth trauma survivors, and 10% of 5–19-year-old birth trauma survivors experience SHS.

Congenital malformations/anomalies

Decedents

- 60% of patients who die from congenital anomalies.(109, 113-115)

Non-Decedents

- As data was not found on the prevalence or longevity of patients with severe congenital malformations, an annual estimate of at least the same number of patients who die of congenital malformations was used for those who do not die, which equals 60% of total deaths.

Injury, poisoning, external causes

Decedents

- 30% of patients who die from injuries (intentional and unintentional).(116, 117) Many patients die so quickly that there is no time to institute palliative care or pain control.

Non-Decedents

- Each year, at least twice the number of patients who die of injuries do not die yet need palliative care or pain control.

Atherosclerosis

Decedents

- 35% of patients who die from other circulatory disease require palliative care.(118, 119)

Musculoskeletal disorders

Decedents

- 70% of patients who die from musculoskeletal diseases require palliative care.(120)

Non-Decedents

- Each year, at least twice the number of patients who die of musculoskeletal disorders do not die yet need palliative care. This category did not include patients with mild pain or with symptoms that do not significantly disrupt social or occupational functioning.

Malnutrition

Decedents

- 100% of deaths from protein-energy malnutrition.(121, 122)

Endocrine, metabolic, blood, and immune disorders

- **Diabetes mellitus:** Although diabetes mellitus in adults is not included due to the high overlap with conditions of other key organs that were already included in the estimate, the expert panel on children's palliative care needs decided to include this condition due to the fact that most of the deaths from diabetes in children are from type-1 diabetes, a congenital condition that can cause SHS without any complication of other key organs. 67% of deaths from diabetes and 10% of survivors with diabetes in children require palliative care. Diabetes mellitus in adults was not included.
- **Thalassemia:** 100% of deaths from thalassemia in children require palliative care. For non-decedents, the expert panel acknowledged that the proportion of patients in need is highly related to the access to treatment, quality of treatment, ability to do transplant and/or regular transfusion. Also, major thalassemia presents different suffering patterns from minor thalassemia. Finally, the panel decided to differentiate the suffering pattern by age groups: for children under 5, 70% and for children 5-19, 10%.
- **Sickle cell disorders:** For children, 100% of deaths and 70% of survivors experience SHS. For adults, previous scholars have found that between 30% and 50% patients living with sickle cell disorders experience pain in most of the days surveyed.(123) Considering other physical and psychological sufferings, 50% of all adult patients living with sickle cell disorders were estimated to experience SHS.

677

678

679

680 **Panel 2: Indicator-specific descriptions, assumptions, and limitations**

Indicator 1: Total symptom-days by condition
<ul style="list-style-type: none">• Description: The sum of the symptom-days from each symptom by condition.• Assumptions and limitations: No weighting of tolerability of symptoms. Assumption that coinciding symptoms make the suffering worse and thus that the symptom-days from each coinciding symptom should be added together. This assumption generates an overestimation of the total number of days of a patient's suffering.
Indicator 2: AT LEAST symptom-days by condition
<ul style="list-style-type: none">• Description: The symptom-days of the one symptom of longest duration. This would be the LEAST or minimal number of symptom-days experienced by the patient.• Assumption and limitation: Assumes that any other symptoms began and ended during period of the symptom of longest duration. In most cases, this will be an underestimate of the total number of days of a patient's suffering.
Indicator 3: AT LEAST non-pain symptom-days by condition
<ul style="list-style-type: none">• Description: The symptom-days of the one non-pain symptom of longest duration. This would be the LEAST or minimal number of non-pain symptom-days experienced by the patient.• Assumption and limitation: Assumes that any other non-pain symptoms began and ended during period of the non-pain symptom of longest duration. In many cases, this will be an underestimate of the total number of days of a patient's suffering from non-pain symptoms.
Indicator 4: Total pain-days by condition
<ul style="list-style-type: none">• Description: The sum of mild pain-days and moderate to severe pain-days.• Assumption and limitation: The mild pain days do not overlap the moderate to severe pain-days. Thus, this indicator shows total days in pain. However, it does not include any other symptoms.
Indicator 5: Pain plus At LEAST non-pain symptom-days by condition
<ul style="list-style-type: none">• Description: This indicator was generated by adding the total pain-days and the AT LEAST non-pain symptom-days (indicator 3).• Assumption and limitation: This is one possible indicator of the burden of suffering for a patient.
Indicator 6: Total days in need of palliative care by condition
<ul style="list-style-type: none">• Description: An estimation of days requiring palliative care by condition by palliative care experts with experience treating patients in LMICs using a Delphi process.• Assumption and limitation: Based only on the opinion of clinical palliative care experts from LMICs in each region.

681

682

683

684 **References**

- 685 1. Knaul FM, Farmer PE, Krakauer EL, et al. Alleviating the access abyss in palliative
686 care and pain relief—an imperative of universal health coverage: the Lancet
687 Commission report. *The Lancet* 2018;391:1391-1454.
- 688 2. United Nations Department of Economic and Social Affairs. Sustainable
689 Development Goals. 2024. Available from: <https://sdgs.un.org/goals>.
- 690 3. World Health Organization. Strengthening of palliative care as a component of
691 comprehensive care throughout the life course. 2014.
- 692 4. Connor S, Bermedo M, Baxter S, et al. Global atlas of palliative care at the end of

693 life. 2014. World Health Organization and Worldwide Palliative Care Alliance 2014.
694 5. Network. GBoDC. Global Burden of Disease Study 2019 (GBD 2019) Results. In:
695 Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2019.
696 6. Krikorian A, Limonero JT. An integrated view of suffering in palliative care.
697 *Journal of palliative care* 2012;28:41-49.
698 7. Gutiérrez-Sánchez D, Gómez-García R, Cuesta-Vargas AI, Pérez-Cruzado D. The
699 suffering measurement instruments in palliative care: A systematic review of
700 psychometric properties. *International Journal of Nursing Studies* 2020;110:103704.
701 8. Knaul FM, Farmer PE, Krakauer EL, et al. Technical Note and Data Appendix for
702 “Alleviating the access abyss in palliative care and pain relief—an imperative of
703 universal health coverage: the Lancet Commission report”. 2017. Available from:
704 [https://www.mia.as.miami.edu/_assets/pdf/data-appendix-lcgapcpc-oct122017_xk-4-](https://www.mia.as.miami.edu/_assets/pdf/data-appendix-lcgapcpc-oct122017_xk-4-22-201.pdf)
705 [22-201.pdf](https://www.mia.as.miami.edu/_assets/pdf/data-appendix-lcgapcpc-oct122017_xk-4-22-201.pdf).
706 9. Amblàs J, Bauer R, Beas E, et al. Building integrated palliative care programs and
707 services. Collaboration with the World Health Organization Collaborating Centre
708 Public Health Palliative Care Programmes 2017.
709 10. Gómez-Batiste X, Connor S, Murray S, et al. Principles, definitions and concepts.
710 *Building Integrated Palliative Care Programs and Services*. Barcelona: Chair of
711 Palliative Care 2017:45-62.
712 11. World Health Organization. Palliative care. 2020. Available from:
713 <https://www.who.int/news-room/fact-sheets/detail/palliative-care>. Accessed Jan 15,
714 2024.
715 12. Radbruch L, De Lima L, Knaul F, et al. Redefining palliative care—a new
716 consensus-based definition. *Journal of pain and symptom management* 2020;60:754-
717 764.
718 13. Almanasreh E, Moles R, Chen TF. Evaluation of methods used for estimating
719 content validity. *Research in social and administrative pharmacy* 2019;15:214-221.
720 14. Dalkey N, Helmer O. An experimental application of the Delphi method to the use
721 of experts. *Management science* 1963;9:458-467.
722 15. McKenna HP. The Delphi technique: a worthwhile research approach for nursing?
723 *Journal of advanced nursing* 1994;19:1221-1225.
724 16. Goodman CM. The Delphi technique: a critique. *Journal of advanced nursing*
725 1987;12:729-734.
726 17. Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a
727 research methodology for nursing. *International journal of nursing studies*
728 2001;38:195-200.
729 18. Connor SR, Downing J, Marston J. Estimating the global need for palliative care
730 for children: a cross-sectional analysis. *Journal of pain and symptom management*
731 2017;53:171-177.
732 19. United Nations. UNAIDS DATA 2019. 2019. Available from:
733 https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf.
734 Accessed Jan 15, 2024.
735 20. International Agency for Research on Cancer. Cancer Today. 2019. Available from:
736 <https://gco.iarc.fr/today/online-analysis->

737 table?v=2020&mode=cancer&mode_population=continents&population=900&popul
738 ations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&popul
739 ation_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=
740 1&include_nmsc=0&include_nmsc_other=1. Accessed Jan 15, 2024.

741 21. Moens K, Higginson IJ, Harding R, et al. Are there differences in the prevalence
742 of palliative care-related problems in people living with advanced cancer and eight
743 non-cancer conditions? A systematic review. *Journal of pain and symptom*
744 *management* 2014;48:660-677.

745 22. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far
746 advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and
747 renal disease. *Journal of pain and symptom management* 2006;31:58-69.

748 23. Becher S, Smith M, Ziran B. Orthopaedic trauma patients and depression: a
749 prospective cohort. *Journal of orthopaedic trauma* 2014;28:e242-e246.

750 24. Alvi T, Minhas FA. Type of presentation of dissociative disorder and frequency of
751 co-morbid depressive disorder. *J Coll Physicians Surg Pak* 2009;19:113-6.

752 25. Pastrana T, Vallath N, Mastrojohn J, et al. Disparities in the contribution of low-
753 and middle-income countries to palliative care research. *Journal of pain and symptom*
754 *management* 2010;39:54-68.

755 26. Nouvet E, Sivaram M, Bezanson K, et al. Palliative care in humanitarian crises: a
756 review of the literature. *Journal of International Humanitarian Action* 2018;3:1-14.

757 27. Rosa WE, Grant L. Focus: Climate Change and Environmental Health: Palliative
758 Justice Post-COP27. *The Yale Journal of Biology and Medicine* 2023;96:257.

759 28. International Labour Office. *The Unpaid Care Work and the Labour Market. An*
760 *analysis of time use data based on the latest World Compilation of Time-use Surveys.*
761 *In: Geneva: International Labour Office, 2019.*

762 29. Brinda EM, Rajkumar AP, Enemark U, Attermann J, Jacob K. Cost and burden of
763 informal caregiving of dependent older people in a rural Indian community. *BMC*
764 *Health Services Research* 2014;14:1-9.

765 30. Schulz R, Sherwood PR. Physical and mental health effects of family caregiving.
766 *Journal of Social Work Education* 2008;44:105-113.

767 31. Rattner M. Increasing our understanding of nonphysical suffering within palliative
768 care: A scoping review. *Palliative & Supportive Care* 2022;20:417-432.

769 32. VanderWeele TJ. Suffering and response: Directions in empirical research. *Social*
770 *Science & Medicine* 2019;224:58-66.

771 33. Bhadelia A, Greaves N, Doubova S, Knaul FM. Understanding the value of
772 alleviating health-related suffering and palliative care centered in lived experience:
773 the SAVE Toolkit. 2023.

774 34. Doubova SV, Bhadelia A, Pérez-Moran D, et al. Dimensions of suffering and the
775 need for palliative care: experiences and expectations of patients living with cancer
776 and diabetes and their caregivers in Mexico—a qualitative study. *BMJ open*
777 2023;13:e075691.

778 35. Pérez-Cruz PE, Undurraga E, Arreola-Ornelas H, et al. Bridging gaps to universal
779 palliative care access in Chile: Serious health-related suffering and the cost of
780 expanding the package of care services. *The Lancet Regional Health—Americas*

781 2023;19.

782 36. Krakauer EL, Kwete XJ, Rassouli M, et al. Palliative care need in the Eastern
783 Mediterranean Region and human resource requirements for effective response. *PLOS*
784 *Global Public Health* 2023;3:e0001980.

785 37. Sleeman KE, Gomes B, de Brito M, Shamieh O, Harding R. The burden of serious
786 health-related suffering among cancer decedents: Global projections study to 2060.
787 *Palliative Medicine* 2021;35:231-235.

788 38. World Health Organization. Assessing the development of palliative care
789 worldwide: a set of actionable indicators. 2021. Available from:
790 <https://www.who.int/publications/i/item/9789240033351>. Accessed Jan15, 2024.

791 39. Krakauer EL, Kwete X, Verguet S, et al. Palliative care and pain control. 2018.

792 40. West TE, von Saint André-von Arnim A. Clinical presentation and management of
793 severe Ebola virus disease. *Annals of the American Thoracic Society* 2014;11:1341-
794 1350.

795 41. Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients
796 with Ebola in Sierra Leone. *New England journal of medicine* 2014;371:2092-2100.

797 42. Dallatomasina S, Crestani R, Sylvester Squire J, et al. Ebola outbreak in rural
798 West Africa: epidemiology, clinical features and outcomes. *Tropical Medicine &*
799 *International Health* 2015;20:448-454.

800 43. MacNeil A, Farnon EC, Wamala J, et al. Proportion of deaths and clinical features
801 in Bundibugyo Ebola virus infection, Uganda. *Emerging infectious diseases*
802 2010;16:1969.

803 44. Boozary AS, Farmer PE, Jha AK. The Ebola outbreak, fragile health systems, and
804 quality as a cure. *Jama* 2014;312:1859-1860.

805 45. Harding R, Foley KM, Connor SR, Jaramillo E. Palliative and end-of-life care in
806 the global response to multidrug-resistant tuberculosis. *The Lancet infectious diseases*
807 2012;12:643-646.

808 46. Organization WH. Companion handbook to the WHO guidelines for the
809 programmatic management of drug-resistant tuberculosis, World Health Organization,
810 2014.

811 47. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of
812 multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. *The*
813 *International Journal of Tuberculosis and Lung Disease* 2004;8:1382-1384.

814 48. Harding R, Selman L, Agupio G, et al. Prevalence, burden, and correlates of
815 physical and psychological symptoms among HIV palliative care patients in sub-
816 Saharan Africa: an international multicenter study. *Journal of pain and symptom*
817 *management* 2012;44:1-9.

818 49. Vogl D, Rosenfeld B, Breitbart W, et al. Symptom prevalence, characteristics, and
819 distress in AIDS outpatients. *Journal of pain and symptom management* 1999;18:253-
820 262.

821 50. McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a
822 hidden epidemic? *Aids* 2010;24:1367-1370.

823 51. Namisango E, Harding R, Atuhaire L, et al. Pain among ambulatory HIV/AIDS
824 patients: multicenter study of prevalence, intensity, associated factors, and effect. *The*

825 Journal of Pain 2012;13:704-713.

826 52. Parker R, Stein DJ, Jelsma J. Pain in people living with HIV/AIDS: a systematic
827 review. *Journal of the International AIDS Society* 2014;17:18719.

828 53. Sims A, Hadigan C. Cardiovascular complications in children with HIV infection.
829 *Current HIV/AIDS Reports* 2011;8:209-214.

830 54. Simms V, Higginson IJ, Harding R. Integration of palliative care throughout HIV
831 disease. *The Lancet Infectious Diseases* 2012;12:571-575.

832 55. Teunissen SCCM, Wesker W, Kruitwagen C, et al. Symptom Prevalence in
833 Patients with Incurable Cancer: A Systematic Review. *Journal of Pain and Symptom*
834 *Management* 2007;34:94-104.

835 56. Tranmer JE, Heyland D, Dudgeon D, et al. Measuring the Symptom Experience of
836 Seriously Ill Cancer and Noncancer Hospitalized Patients Near the End of Life with
837 the Memorial Symptom Assessment Scale. *Journal of Pain and Symptom*
838 *Management* 2003;25:420-429.

839 57. van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-
840 Heijnen VCG, Janssen DJA. Update on Prevalence of Pain in Patients With Cancer:
841 Systematic Review and Meta-Analysis. *Journal of Pain and Symptom Management*
842 2016;51:1070-1090.e9.

843 58. International Agency for Research on Cancer. Global Cancer Observatory, Cancer
844 Facts Sheet. 2019. Available from: <https://gco.iarc.fr/>. Accessed Jan 15, 2024.

845 59. Shi Q, Smith TG, Michonski JD, et al. Symptom burden in cancer survivors 1 year
846 after diagnosis. *Cancer* 2011;117:2779-2790.

847 60. Zucca AC, Boyes AW, Linden W, Girgis A. All's Well That Ends Well? Quality of
848 Life and Physical Symptom Clusters in Long-Term Cancer Survivors Across Cancer
849 Types. *Journal of Pain and Symptom Management* 2012;43:720-731.

850 61. Mitchell SL, Teno JM, Kiely DK, et al. The Clinical Course of Advanced
851 Dementia. *New England Journal of Medicine* 2009;361:1529-1538.

852 62. American Geriatrics Society Ethics C, Clinical P, Models of Care C. American
853 Geriatrics Society Feeding Tubes in Advanced Dementia Position Statement. *Journal*
854 *of the American Geriatrics Society* 2014;62:1590-1593.

855 63. Teno JM, Gozalo PL, Lee IC, et al. Does Hospice Improve Quality of Care for
856 Persons Dying from Dementia? *Journal of the American Geriatrics Society*
857 2011;59:1531-1536.

858 64. Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and
859 other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease.
860 *Journal of Neurology* 2010;257:1073-1082.

861 65. Dissanayaka NNW, Sellbach A, Matheson S, et al. Anxiety disorders in
862 Parkinson's disease: Prevalence and risk factors. *Movement Disorders* 2010;25:838-
863 845.

864 66. Rosenbaum RB. *Understanding Parkinson's disease: a personal and professional*
865 *view*, Bloomsbury Publishing USA, 2006.

866 67. Téllez-Zenteno JF, Ronquillo LH, Moien-Afshari F, Wiebe S. Surgical outcomes
867 in lesional and non-lesional epilepsy: A systematic review and meta-analysis.
868 *Epilepsy Research* 2010;89:310-318.

- 869 68. de Cerqueira AC, Semionato de Andrade P, Godoy Barreiros JM, Teixeira AL,
870 Nardi AE. Psychiatric disorders in patients with multiple sclerosis. *Comprehensive*
871 *Psychiatry* 2015;63:10-14.
- 872 69. Patterson K, Marshall JC, Coltheart M. *Surface dyslexia: Neuropsychological and*
873 *cognitive studies of phonological reading.*, Routledge, 2017.
- 874 70. Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: A
875 growing global problem with widespread inequity. *Neurology* 2014;83:1022-1024.
- 876 71. Rolak LA. Multiple Sclerosis: It's Not The Disease You Thought It Was. *Clinical*
877 *Medicine & Research* 2003;1:57-60.
- 878 72. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple
879 sclerosis. *Neurology* 2014;83:278-286.
- 880 73. Brønnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with
881 multiple sclerosis in Denmark. *Neurology* 1994;44:1901-1901.
- 882 74. Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson's
883 disease. *Movement Disorders* 2015;30:1442-1450.
- 884 75. Shang Q, Ma CY, Lv N, et al. Clinical study of cerebral palsy in 408 children with
885 periventricular leukomalacia. *Exp Ther Med* 2015;9:1336-1344.
- 886 76. Hirsh AT, Gallegos JC, Gertz KJ, Engel JM, Jensen MP. Symptom burden in
887 individuals with cerebral palsy. *J Rehabil Res Dev* 2010;47:863-76.
- 888 77. About Parkinson's. 2024. Available from: [http://www.epda.eu.com/about-](http://www.epda.eu.com/about-parkinson-s/)
889 [parkinson-s/](http://www.epda.eu.com/about-parkinson-s/). Accessed Jan 15, 2024.
- 890 78. Schnitzler A, Woimant F, Nicolau J, Tuppin P, de Peretti C. Effect of
891 Rehabilitation Setting on Dependence Following Stroke: An Analysis of the French
892 Inpatient Database. *Neurorehabilitation and Neural Repair* 2013;28:36-44.
- 893 79. Krishnamurthi RV, Moran AE, Feigin VL, et al. Stroke Prevalence, Mortality and
894 Disability-Adjusted Life Years in Adults Aged 20-64 Years in 1990-2013: Data from
895 the Global Burden of Disease 2013 Study. *Neuroepidemiology* 2015;45:190-202.
- 896 80. Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the Global Burden of
897 Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study.
898 *Neuroepidemiology* 2015;45:161-176.
- 899 81. Boysen G, Marott JL, Grønbaek M, Hassanpour H, Truelsen T. Long-Term
900 Survival after Stroke: 30 Years of Follow-Up in a Cohort, the Copenhagen City Heart
901 Study. *Neuroepidemiology* 2009;33:254-260.
- 902 82. Brønnum-Hansen H, Davidsen M, Thorvaldsen P. Long-Term Survival and
903 Causes of Death After Stroke. *Stroke* 2001;32:2131-2136.
- 904 83. De Wit L, Putman K, Baert I, et al. Anxiety and depression in the first six months
905 after stroke. A longitudinal multicentre study. *Disability and Rehabilitation*
906 *2008;30:1858-1866.*
- 907 84. Broomfield NM, Quinn TJ, Abdul-Rahim AH, Walters MR, Evans JJ. Depression
908 and anxiety symptoms post-stroke/TIA: prevalence and associations in cross-sectional
909 data from a regional stroke registry. *BMC Neurology* 2014;14:198.
- 910 85. Klimiec E, Dziedzic T, Kowalska K, et al. PROspective Observational POLish
911 Study on post-stroke delirium (PROPOLIS): methodology of hospital-based cohort
912 study on delirium prevalence, predictors and diagnostic tools. *BMC Neurology*

913 2015;15:94.

914 86. Brainin M, Heiss W-D. extbook of stroke medicine, Cambridge University Press,
915 2019.

916 87. Rustad JK, Stern TA, Hebert KA, Musselman DL. Diagnosis and treatment of
917 depression in patients with congestive heart failure: a review of the literature. The
918 primary care companion for CNS disorders 2013;15:26254.

919 88. Ahmed A, Rich MW, Fleg JL, et al. Effects of Digoxin on Morbidity and Mortality
920 in Diastolic Heart Failure. *Circulation* 2006;114:397-403.

921 89. Cully JA, Johnson M, Moffett ML, Khan M, Deswal A. Depression and Anxiety
922 in Ambulatory Patients With Heart Failure. *Psychosomatics* 2009;50:592-598.

923 90. Jiang W, Kuchibhatla M, Cuffe MS, et al. Prognostic Value of Anxiety and
924 Depression in Patients With Chronic Heart Failure. *Circulation* 2004;110:3452-3456.

925 91. Havranek EP, Ware MG, Lowes BD. Prevalence of depression in congestive heart
926 failure. *American Journal of Cardiology* 1999;84:348-350.

927 92. Vaccarino V, Kasl Stanislav V, Abramson J, Krumholz Harlan M. Depressive
928 symptoms and risk of functional decline and death in patients with heart failure.
929 *Journal of the American College of Cardiology* 2001;38:199-205.

930 93. Bankier B, Januzzi JL, Littman AB. The High Prevalence of Multiple Psychiatric
931 Disorders in Stable Outpatients With Coronary Heart Disease. *Psychosomatic*
932 *Medicine* 2004;66.

933 94. Ley B, Collard HR, King TE. Clinical Course and Prediction of Survival in
934 Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care*
935 *Medicine* 2011;183:431-440.

936 95. Lanken PN, Terry PB, DeLisser HM, et al. An Official American Thoracic Society
937 Clinical Policy Statement: Palliative Care for Patients with Respiratory Diseases and
938 Critical Illnesses. *American Journal of Respiratory and Critical Care Medicine*
939 2008;177:912-927.

940 96. John H, Kevin G-J, June R, et al. The distribution of COPD in UK general
941 practice using the new GOLD classification. *European Respiratory Journal*
942 2014;43:993.

943 97. Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications:
944 evidence based treatment. *World J Gastroenterol* 2014;20:5442-60.

945 98. Bianchi G, Marchesini G, Nicolino F, et al. Psychological status and depression in
946 patients with liver cirrhosis. *Digestive and Liver Disease* 2005;37:593-600.

947 99. Aghanwa HS, Ndububa D. Specific psychiatric morbidity in liver cirrhosis in a
948 Nigerian general hospital setting. *General Hospital Psychiatry* 2002;24:436-441.

949 100. Weissenborn K, Bokemeyer M, Krause J, Ennen J, Ahl B. Neurological and
950 neuropsychiatric syndromes associated with liver disease. *AIDS* 2005;19.

951 101. Nardelli S, Pentassuglio I, Pasquale C, et al. Depression, anxiety and alexithymia
952 symptoms are major determinants of health related quality of life (HRQoL) in
953 cirrhotic patients. *Metabolic Brain Disease* 2013;28:239-243.

954 102. Peng J-K, Hepgul N, Higginson IJ, Gao W. Symptom prevalence and quality of
955 life of patients with end-stage liver disease: A systematic review and meta-analysis.
956 *Palliative Medicine* 2018;33:24-36.

- 957 103. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators
958 of survival in cirrhosis: A systematic review of 118 studies. *Journal of Hepatology*
959 2006;44:217-231.
- 960 104. Murtagh FEM, Addington-Hall JM, Edmonds PM, et al. Symptoms in Advanced
961 Renal Disease: A Cross-Sectional Survey of Symptom Prevalence in Stage 5 Chronic
962 Kidney Disease Managed without Dialysis. *Journal of Palliative Medicine*
963 2007;10:1266-1276.
- 964 105. Weisbord SD, Carmody SS, Bruns FJ, et al. Symptom burden, quality of life,
965 advance care planning and the potential value of palliative care in severely ill
966 haemodialysis patients. *Nephrology Dialysis Transplantation* 2003;18:1345-1352.
- 967 106. Cohen LM, Moss AH, Weisbord SD, Germain MJ. Renal Palliative Care. *Journal*
968 *of Palliative Medicine* 2006;9:977-992.
- 969 107. Himmelstein BP, Hilden JM, Boldt AM, Weissman D. Pediatric Palliative Care.
970 *New England Journal of Medicine* 2004;350:1752-1762.
- 971 108. Connor SR, Sisimay C. Assessment of the need for palliative care for children:
972 three country report: South Africa, Kenya and Zimbabwe. In: London: United Nations
973 Children's Fund (UNICEF), International Children's Palliative Care Network
974 (ICPCN), 2013.
- 975 109. Kenner C, Press J, Ryan D. Recommendations for palliative and bereavement
976 care in the NICU: a family-centered integrative approach. *Journal of Perinatology*
977 2015;35:S19-S23.
- 978 110. Madden K, Wolfe J, Collura C. Pediatric Palliative Care in the Intensive Care
979 Unit. *Critical Care Nursing Clinics* 2015;27:341-354.
- 980 111. McCormick MC, Brooks-Gunn J, Buka SL, et al. Early Intervention in Low Birth
981 Weight Premature Infants: Results at 18 Years of Age for the Infant Health and
982 Development Program. *Pediatrics* 2006;117:771-780.
- 983 112. Dastgiri S, Gilmour WH, Stone DH. Survival of children born with congenital
984 anomalies. *Arch Dis Child* 2003;88:391-4.
- 985 113. World Health Organization. Birth defects: report by the Secretariat. In: Geneva:
986 WHO, 2010.
- 987 114. Mosenthal AC, Murphy PA. Trauma Care and Palliative Care: Time to Integrate
988 the Two? *Journal of the American College of Surgeons* 2003;197.
- 989 115. Holbrook TL, Galarneau MR, Dye JL, Quinn K, Dougherty AL. Morphine Use
990 after Combat Injury in Iraq and Post-Traumatic Stress Disorder. *New England Journal*
991 *of Medicine* 2010;362:110-117.
- 992 116. Jones WS, Schmit KM, Vemulapalli S, et al. Treatment Strategies for Patients
993 With Peripheral Artery Disease. In: Agency for Healthcare Research and Quality (US),
994 Rockville (MD), 2013.
- 995 117. Bendermacher BLW, Willigendael EM, Teijink JAW, Prins MH. Medical
996 management of peripheral arterial disease. *Journal of Thrombosis and Haemostasis*
997 2005;3:1628-1637.
- 998 118. Woolf AD, Pflieger B. Burden of major musculoskeletal conditions. *Bulletin of*
999 *the World Health Organization* 2003;2003:646-656.
- 1000 119. Belachew T, Nekatibeb H. Assessment of outpatient therapeutic programme for

1001 severe acute malnutrition in three regions of Ethiopia. East African medical journal
1002 2007;84:577-588.

1003 120. World Health Organization. The treatment and management of severe protein-
1004 energy malnutrition. In: Geneva, Switzerland: WHO, 1981.

1005 121. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily Assessment of Pain in
1006 Adults with Sickle Cell Disease. Annals of Internal Medicine 2008;148:94-101.
1007
1008

1009 1. Knaul FM, Farmer PE, Krakauer EL, et al. Alleviating the access abyss in palliative care
1010 and pain relief—an imperative of universal health coverage: the Lancet Commission report.
1011 The Lancet 2018;391:1391-1454.

1012 2. United Nations Department of Economic and Social Affairs. Sustainable Development
1013 Goals. 2024. Available from: <https://sdgs.un.org/goals>.

1014 3. World Health Organization. Strengthening of palliative care as a component of
1015 comprehensive care throughout the life course. 2014.

1016 4. Connor S, Bernedo M, Baxter S, et al. Global atlas of palliative care at the end of life.
1017 2014. World Health Organization and Worldwide Palliative Care Alliance 2014.

1018 5. Network. GBoDC. Global Burden of Disease Study 2019 (GBD 2019) Results. In: Seattle,
1019 United States: Institute for Health Metrics and Evaluation (IHME), 2019.

1020 6. Krikorian A, Limonero JT. An integrated view of suffering in palliative care. Journal of
1021 palliative care 2012;28:41-49.

1022 7. Gutiérrez-Sánchez D, Gómez-García R, Cuesta-Vargas AI, Pérez-Cruzado D. The
1023 suffering measurement instruments in palliative care: A systematic review of psychometric
1024 properties. International Journal of Nursing Studies 2020;110:103704.

1025 8. Knaul FM, Farmer PE, Krakauer EL, et al. Technical Note and Data Appendix for
1026 “Alleviating the access abyss in palliative care and pain relief—an imperative of universal

1027 health coverage: the Lancet Commission report". 2017. Available from:
1028 https://www.mia.as.miami.edu/_assets/pdf/data-appendix-lcgapcpc-oct122017_xk-4-22-
1029 [201.pdf](#).

1030 9. International Narcotic Control Board. Progress in ensuring adequate access to
1031 internationally controlled substances for medical and scientific purposes. In: Vienna :: UN,
1032 2019.

1033 10. Connor S, Morris C, Jaramillo E, et al. Global Atlas of Palliative Care (2nd Edition). In:
1034 London, UK: Worldwide Palliative Care Alliance, 2020.

1035 11. Krakauer EL, Kwete X, Verguet S, et al. Palliative care and pain control. 2018.

1036 12. Radbruch L, De Lima L, Knaut F, et al. Redefining palliative care—a new consensus-
1037 based definition. *Journal of pain and symptom management* 2020;60:754-764.

1038 13. World Health Organization. Palliative care. 2020. Available from:
1039 <https://www.who.int/news-room/fact-sheets/detail/palliative-care>. Accessed Jan 15, 2024.

1040 14. Almanasreh E, Moles R, Chen TF. Evaluation of methods used for estimating content
1041 validity. *Research in social and administrative pharmacy* 2019;15:214-221.

1042 15. Dalkey N, Helmer O. An experimental application of the Delphi method to the use of
1043 experts. *Management science* 1963;9:458-467.

1044 16. McKenna HP. The Delphi technique: a worthwhile research approach for nursing? *Journal*
1045 *of advanced nursing* 1994;19:1221-1225.

1046 17. Goodman CM. The Delphi technique: a critique. *Journal of advanced nursing*
1047 1987;12:729-734.

1048 18. Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a
1049 research methodology for nursing. *International journal of nursing studies* 2001;38:195-200.

1050 19. Connor SR, Downing J, Marston J. Estimating the global need for palliative care for
1051 children: a cross-sectional analysis. *Journal of pain and symptom management* 2017;53:171-
1052 177.

1053 20. United Nations. UNAIDS DATA 2019. 2019. Available from:
1054 https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf. Accessed
1055 Jan 15, 2024.

1056 21. International Agency for Research on Cancer. Cancer Today. 2019. Available from:
1057 [https://gco.iarc.fr/today/online-analysis-
1058 \[table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1\]\(https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1\). Accessed Jan 15, 2024.](https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1)

1062 22. Alnajar M, Darawad M, Khater W, et al. Exploring Palliative Care Needs Among Patients
1063 With Cancer and Non-Cancer Serious Chronic Diseases: A Comparison Study. *Am J Hosp
1064 Palliat Care* 2024;10499091241235920.

1065 23. Calsina-Berna A, Amblàs Novellas J, González-Barboteo J, et al. Prevalence and clinical
1066 characteristics of patients with Advanced Chronic Illness and Palliative Care needs, identified
1067 with the NECPAL CCOMS-ICO© Tool at a Tertiary Care Hospital. *BMC Palliat Care*
1068 2022;21:210.

- 1069 24. Moens K, Higginson IJ, Harding R, et al. Are there differences in the prevalence of
1070 palliative care-related problems in people living with advanced cancer and eight non-cancer
1071 conditions? A systematic review. *Journal of pain and symptom management* 2014;48:660-
1072 677.
- 1073 25. Islam N, Biswas J, Kowshik MM, et al. Depression, anxiety, and performance status
1074 among the women with metastatic breast cancer receiving palliative care in Bangladesh: A
1075 cross sectional study. *Health Sci Rep* 2022;5:e911.
- 1076 26. Abbas M, Reich AJ, Wang Y, et al. The burden of pre-admission pain, depression, and
1077 caregiving on palliative care needs for seriously ill trauma patients. *J Am Geriatr Soc*
1078 2023;71:2229-2238.
- 1079 27. Pastrana T, Vallath N, Mastrojohn J, et al. Disparities in the contribution of low-and
1080 middle-income countries to palliative care research. *Journal of pain and symptom*
1081 *management* 2010;39:54-68.
- 1082 28. Nouvet E, Sivaram M, Bezanson K, et al. Palliative care in humanitarian crises: a review
1083 of the literature. *Journal of International Humanitarian Action* 2018;3:1-14.
- 1084 29. Rosa WE, Grant L. Focus: Climate Change and Environmental Health: Palliative Justice
1085 Post-COP27. *The Yale Journal of Biology and Medicine* 2023;96:257.
- 1086 30. International Labour Office. *The Unpaid Care Work and the Labour Market. An analysis of*
1087 *time use data based on the latest World Compilation of Time-use Surveys.* In: Geneva:
1088 International Labour Office, 2019.

1089 31. Oechsle K, Ullrich A, Marx G, et al. Psychological burden in family caregivers of patients
1090 with advanced cancer at initiation of specialist inpatient palliative care. *BMC Palliat Care*
1091 2019;18:102.

1092 32. Dipio R, Acuda W, Namisango E, Nalubega-Mbowa MG. Prevalence and factors
1093 associated with depressive symptoms among family caregivers of palliative care patients at
1094 Hospice Africa Uganda. *Palliat Support Care* 2022;20:375-382.

1095 33. Rattner M. Increasing our understanding of nonphysical suffering within palliative care: A
1096 scoping review. *Palliative & Supportive Care* 2022;20:417-432.

1097 34. VanderWeele TJ. Suffering and response: Directions in empirical research. *Social*
1098 *Science & Medicine* 2019;224:58-66.

1099 35. Bhadelia A, Greaves N, Doubova S, Knaul FM. Understanding the value of alleviating
1100 health-related suffering and palliative care centered in lived experience: the SAVE Toolkit.
1101 2023.

1102 36. Doubova SV, Bhadelia A, Pérez-Moran D, et al. Dimensions of suffering and the need for
1103 palliative care: experiences and expectations of patients living with cancer and diabetes and
1104 their caregivers in Mexico—a qualitative study. *BMJ open* 2023;13:e075691.

1105 37. Pérez-Cruz PE, Undurraga E, Arreola-Ornelas H, et al. Bridging gaps to universal
1106 palliative care access in Chile: Serious health-related suffering and the cost of expanding the
1107 package of care services. *The Lancet Regional Health—Americas* 2023;19.

1108 38. Krakauer EL, Kwete XJ, Rassouli M, et al. Palliative care need in the Eastern
1109 Mediterranean Region and human resource requirements for effective response. *PLOS*
1110 *Global Public Health* 2023;3:e0001980.

1111 39. Sleeman KE, Gomes B, de Brito M, Shamieh O, Harding R. The burden of serious health-
1112 related suffering among cancer decedents: Global projections study to 2060. Palliative
1113 Medicine 2021;35:231-235.

1114 40. World Health Organization. Assessing the development of palliative care worldwide: a set
1115 of actionable indicators. 2021. Available from:
1116 <https://www.who.int/publications/i/item/9789240033351>. Accessed Jan15, 2024.

1117 41. West TE, von Saint André-von Arnim A. Clinical presentation and management of severe
1118 Ebola virus disease. Annals of the American Thoracic Society 2014;11:1341-1350.

1119 42. Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with
1120 Ebola in Sierra Leone. New England journal of medicine 2014;371:2092-2100.

1121 43. Dallatomasina S, Crestani R, Sylvester Squire J, et al. Ebola outbreak in rural West
1122 Africa: epidemiology, clinical features and outcomes. Tropical Medicine & International Health
1123 2015;20:448-454.

1124 44. MacNeil A, Farnon EC, Wamala J, et al. Proportion of deaths and clinical features in
1125 Bundibugyo Ebola virus infection, Uganda. Emerging infectious diseases 2010;16:1969.

1126 45. Boozary AS, Farmer PE, Jha AK. The Ebola outbreak, fragile health systems, and quality
1127 as a cure. Jama 2014;312:1859-1860.

1128 46. Harding R, Foley KM, Connor SR, Jaramillo E. Palliative and end-of-life care in the global
1129 response to multidrug-resistant tuberculosis. The Lancet infectious diseases 2012;12:643-
1130 646.

1131 47. Organization WH. Companion handbook to the WHO guidelines for the programmatic
1132 management of drug-resistant tuberculosis, World Health Organization, 2014.

1133 48. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-
1134 resistant tuberculosis: results from the DOTS-Plus initiative. *The International Journal of*
1135 *Tuberculosis and Lung Disease* 2004;8:1382-1384.

1136 49. Harding R, Selman L, Agupio G, et al. Prevalence, burden, and correlates of physical and
1137 psychological symptoms among HIV palliative care patients in sub-Saharan Africa: an
1138 international multicenter study. *Journal of pain and symptom management* 2012;44:1-9.

1139 50. Vogl D, Rosenfeld B, Breitbart W, et al. Symptom prevalence, characteristics, and distress
1140 in AIDS outpatients. *Journal of pain and symptom management* 1999;18:253-262.

1141 51. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced
1142 cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease.
1143 *Journal of pain and symptom management* 2006;31:58-69.

1144 52. McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden
1145 epidemic? *Aids* 2010;24:1367-1370.

1146 53. Namisango E, Harding R, Atuhaire L, et al. Pain among ambulatory HIV/AIDS patients:
1147 multicenter study of prevalence, intensity, associated factors, and effect. *The Journal of Pain*
1148 2012;13:704-713.

1149 54. Parker R, Stein DJ, Jelsma J. Pain in people living with HIV/AIDS: a systematic review.
1150 *Journal of the International AIDS Society* 2014;17:18719.

1151 55. Sims A, Hadigan C. Cardiovascular complications in children with HIV infection. *Current*
1152 *HIV/AIDS Reports* 2011;8:209-214.

1153 56. Simms V, Higginson IJ, Harding R. Integration of palliative care throughout HIV disease.
1154 *The Lancet Infectious Diseases* 2012;12:571-575.

1155 57. Teunissen SCCM, Wesker W, Kruitwagen C, et al. Symptom Prevalence in Patients with
1156 Incurable Cancer: A Systematic Review. Journal of Pain and Symptom Management
1157 2007;34:94-104.

1158 58. Tranmer JE, Heyland D, Dudgeon D, et al. Measuring the Symptom Experience of
1159 Seriously Ill Cancer and Noncancer Hospitalized Patients Near the End of Life with the
1160 Memorial Symptom Assessment Scale. Journal of Pain and Symptom Management
1161 2003;25:420-429.

1162 59. van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen
1163 VCG, Janssen DJA. Update on Prevalence of Pain in Patients With Cancer: Systematic
1164 Review and Meta-Analysis. Journal of Pain and Symptom Management 2016;51:1070-
1165 1090.e9.

1166 60. International Agency for Research on Cancer. Global Cancer Observatory, Cancer Facts
1167 Sheet. 2019. Available from: <https://gco.iarc.fr/>. Accessed Jan 15, 2024.

1168 61. Shi Q, Smith TG, Michonski JD, et al. Symptom burden in cancer survivors 1 year after
1169 diagnosis. Cancer 2011;117:2779-2790.

1170 62. Zucca AC, Boyes AW, Linden W, Girgis A. All's Well That Ends Well? Quality of Life and
1171 Physical Symptom Clusters in Long-Term Cancer Survivors Across Cancer Types. Journal of
1172 Pain and Symptom Management 2012;43:720-731.

1173 63. Mitchell SL, Teno JM, Kiely DK, et al. The Clinical Course of Advanced Dementia. New
1174 England Journal of Medicine 2009;361:1529-1538.

1175 64. American Geriatrics Society Ethics C, Clinical P, Models of Care C. American Geriatrics
1176 Society Feeding Tubes in Advanced Dementia Position Statement. Journal of the American
1177 Geriatrics Society 2014;62:1590-1593.

1178 65. Teno JM, Gozalo PL, Lee IC, et al. Does Hospice Improve Quality of Care for Persons
1179 Dying from Dementia? Journal of the American Geriatrics Society 2011;59:1531-1536.

1180 66. Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other
1181 neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. Journal of
1182 Neurology 2010;257:1073-1082.

1183 67. Dissanayaka NNW, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson's
1184 disease: Prevalence and risk factors. Movement Disorders 2010;25:838-845.

1185 68. Rosenbaum RB. Understanding Parkinson's disease: a personal and professional view,
1186 Bloomsbury Publishing USA, 2006.

1187 69. Téllez-Zenteno JF, Ronquillo LH, Moien-Afshari F, Wiebe S. Surgical outcomes in lesional
1188 and non-lesional epilepsy: A systematic review and meta-analysis. Epilepsy Research
1189 2010;89:310-318.

1190 70. de Cerqueira AC, Semionato de Andrade P, Godoy Barreiros JM, Teixeira AL, Nardi AE.
1191 Psychiatric disorders in patients with multiple sclerosis. Comprehensive Psychiatry
1192 2015;63:10-14.

1193 71. Patterson K, Marshall JC, Coltheart M. Surface dyslexia: Neuropsychological and
1194 cognitive studies of phonological reading., Routledge, 2017.

1195 72. Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: A growing
1196 global problem with widespread inequity. Neurology 2014;83:1022-1024.

1197 73. Rolak LA. Multiple Sclerosis: It's Not The Disease You Thought It Was. *Clinical Medicine*
1198 & Research 2003;1:57-60.

1199 74. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis.
1200 *Neurology* 2014;83:278-286.

1201 75. Brønnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with multiple
1202 sclerosis in Denmark. *Neurology* 1994;44:1901-1901.

1203 76. Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson's disease.
1204 *Movement Disorders* 2015;30:1442-1450.

1205 77. Shang Q, Ma CY, Lv N, et al. Clinical study of cerebral palsy in 408 children with
1206 periventricular leukomalacia. *Exp Ther Med* 2015;9:1336-1344.

1207 78. Hirsh AT, Gallegos JC, Gertz KJ, Engel JM, Jensen MP. Symptom burden in individuals
1208 with cerebral palsy. *J Rehabil Res Dev* 2010;47:863-76.

1209 79. About Parkinson's. 2024. Available from: <http://www.epda.eu.com/about-parkinson-s/>.
1210 Accessed Jan 15, 2024.

1211 80. Schnitzler A, Woimant F, Nicolau J, Tuppin P, de Peretti C. Effect of Rehabilitation Setting
1212 on Dependence Following Stroke: An Analysis of the French Inpatient Database.
1213 *Neurorehabilitation and Neural Repair* 2013;28:36-44.

1214 81. Krishnamurthi RV, Moran AE, Feigin VL, et al. Stroke Prevalence, Mortality and Disability-
1215 Adjusted Life Years in Adults Aged 20-64 Years in 1990-2013: Data from the Global Burden
1216 of Disease 2013 Study. *Neuroepidemiology* 2015;45:190-202.

1217 82. Feigin VL, Krishnamurthi RV, Pamar P, et al. Update on the Global Burden of Ischemic
1218 and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. *Neuroepidemiology*
1219 2015;45:161-176.

1220 83. Boysen G, Marott JL, Grønbaek M, Hassanpour H, Truelsen T. Long-Term Survival after
1221 Stroke: 30 Years of Follow-Up in a Cohort, the Copenhagen City Heart Study.
1222 *Neuroepidemiology* 2009;33:254-260.

1223 84. Brønnum-Hansen H, Davidsen M, Thorvaldsen P. Long-Term Survival and Causes of
1224 Death After Stroke. *Stroke* 2001;32:2131-2136.

1225 85. De Wit L, Putman K, Baert I, et al. Anxiety and depression in the first six months after
1226 stroke. A longitudinal multicentre study. *Disability and Rehabilitation* 2008;30:1858-1866.

1227 86. Broomfield NM, Quinn TJ, Abdul-Rahim AH, Walters MR, Evans JJ. Depression and
1228 anxiety symptoms post-stroke/TIA: prevalence and associations in cross-sectional data from
1229 a regional stroke registry. *BMC Neurology* 2014;14:198.

1230 87. Klimiec E, Dziedzic T, Kowalska K, et al. PRospective Observational POLish Study on
1231 post-stroke delirium (PROPOLIS): methodology of hospital-based cohort study on delirium
1232 prevalence, predictors and diagnostic tools. *BMC Neurology* 2015;15:94.

1233 88. Brainin M, Heiss W-D. *Textbook of stroke medicine*, Cambridge University Press, 2019.

1234 89. Rustad JK, Stern TA, Hebert KA, Musselman DL. Diagnosis and treatment of depression
1235 in patients with congestive heart failure: a review of the literature. The primary care
1236 companion for CNS disorders 2013;15:26254.

1237 90. Ahmed A, Rich MW, Fleg JL, et al. Effects of Digoxin on Morbidity and Mortality in
1238 Diastolic Heart Failure. *Circulation* 2006;114:397-403.

1239 91. Cully JA, Johnson M, Moffett ML, Khan M, Deswal A. Depression and Anxiety in
1240 Ambulatory Patients With Heart Failure. *Psychosomatics* 2009;50:592-598.

1241 92. Jiang W, Kuchibhatla M, Cuffe MS, et al. Prognostic Value of Anxiety and Depression in
1242 Patients With Chronic Heart Failure. *Circulation* 2004;110:3452-3456.

1243 93. Havranek EP, Ware MG, Lowes BD. Prevalence of depression in congestive heart failure.
1244 *American Journal of Cardiology* 1999;84:348-350.

1245 94. Vaccarino V, Kasl Stanislav V, Abramson J, Krumholz Harlan M. Depressive symptoms
1246 and risk of functional decline and death in patients with heart failure. *Journal of the American*
1247 *College of Cardiology* 2001;38:199-205.

1248 95. Bankier B, Januzzi JL, Littman AB. The High Prevalence of Multiple Psychiatric Disorders
1249 in Stable Outpatients With Coronary Heart Disease. *Psychosomatic Medicine* 2004;66.

1250 96. Ley B, Collard HR, King TE. Clinical Course and Prediction of Survival in Idiopathic
1251 Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*
1252 2011;183:431-440.

1253 97. Lanken PN, Terry PB, DeLisser HM, et al. An Official American Thoracic Society Clinical
1254 Policy Statement: Palliative Care for Patients with Respiratory Diseases and Critical Illnesses.
1255 *American Journal of Respiratory and Critical Care Medicine* 2008;177:912-927.

1256 98. John H, Kevin G-J, June R, et al. The distribution of COPD in UK general practice using
1257 the new GOLD classification. *European Respiratory Journal* 2014;43:993.

1258 99. Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence
1259 based treatment. *World J Gastroenterol* 2014;20:5442-60.

1260 100. Bianchi G, Marchesini G, Nicolino F, et al. Psychological status and depression in
1261 patients with liver cirrhosis. *Digestive and Liver Disease* 2005;37:593-600.

1262 101. Aghanwa HS, Ndububa D. Specific psychiatric morbidity in liver cirrhosis in a Nigerian
1263 general hospital setting. *General Hospital Psychiatry* 2002;24:436-441.

1264 102. Weissenborn K, Bokemeyer M, Krause J, Ennen J, Ahl B. Neurological and
1265 neuropsychiatric syndromes associated with liver disease. *AIDS* 2005;19.

1266 103. Nardelli S, Pentassuglio I, Pasquale C, et al. Depression, anxiety and alexithymia
1267 symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic
1268 patients. *Metabolic Brain Disease* 2013;28:239-243.

1269 104. Peng J-K, Heggul N, Higginson IJ, Gao W. Symptom prevalence and quality of life of
1270 patients with end-stage liver disease: A systematic review and meta-analysis. *Palliative*
1271 *Medicine* 2018;33:24-36.

1272 105. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of
1273 survival in cirrhosis: A systematic review of 118 studies. *Journal of Hepatology* 2006;44:217-
1274 231.

1275 106. Murtagh FEM, Addington-Hall JM, Edmonds PM, et al. Symptoms in Advanced Renal
1276 Disease: A Cross-Sectional Survey of Symptom Prevalence in Stage 5 Chronic Kidney
1277 Disease Managed without Dialysis. *Journal of Palliative Medicine* 2007;10:1266-1276.

1278 107. Weisbord SD, Carmody SS, Bruns FJ, et al. Symptom burden, quality of life, advance
1279 care planning and the potential value of palliative care in severely ill haemodialysis patients.
1280 *Nephrology Dialysis Transplantation* 2003;18:1345-1352.

1281 108. Cohen LM, Moss AH, Weisbord SD, Germain MJ. Renal Palliative Care. Journal of
1282 Palliative Medicine 2006;9:977-992.

1283 109. Himmelstein BP, Hilden JM, Boldt AM, Weissman D. Pediatric Palliative Care. New
1284 England Journal of Medicine 2004;350:1752-1762.

1285 110. Connor SR, Sisimay C. Assessment of the need for palliative care for children: three
1286 country report: South Africa, Kenya and Zimbabwe. In: London: United Nations Children's
1287 Fund (UNICEF), International Children's Palliative Care Network (ICPCN), 2013.

1288 111. Kenner C, Press J, Ryan D. Recommendations for palliative and bereavement care in
1289 the NICU: a family-centered integrative approach. Journal of Perinatology 2015;35:S19-S23.

1290 112. Madden K, Wolfe J, Collura C. Pediatric Palliative Care in the Intensive Care Unit.
1291 Critical Care Nursing Clinics 2015;27:341-354.

1292 113. McCormick MC, Brooks-Gunn J, Buka SL, et al. Early Intervention in Low Birth Weight
1293 Premature Infants: Results at 18 Years of Age for the Infant Health and Development
1294 Program. Pediatrics 2006;117:771-780.

1295 114. Dastgiri S, Gilmour WH, Stone DH. Survival of children born with congenital anomalies.
1296 Arch Dis Child 2003;88:391-4.

1297 115. World Health Organization. Birth defects: report by the Secretariat. In: Geneva: WHO,
1298 2010.

1299 116. Mosenthal AC, Murphy PA. Trauma Care and Palliative Care: Time to Integrate the
1300 Two? Journal of the American College of Surgeons 2003;197.

1301 117. Holbrook TL, Galarnau MR, Dye JL, Quinn K, Dougherty AL. Morphine Use after
1302 Combat Injury in Iraq and Post-Traumatic Stress Disorder. *New England Journal of Medicine*
1303 2010;362:110-117.

1304 118. Jones WS, Schmit KM, Vemulapalli S, et al. Treatment Strategies for Patients With
1305 Peripheral Artery Disease. In: Agency for Healthcare Research and Quality (US), Rockville
1306 (MD), 2013.

1307 119. Bendemacher BLW, Willigendael EM, Teijink JAW, Prins MH. Medical management of
1308 peripheral arterial disease. *Journal of Thrombosis and Haemostasis* 2005;3:1628-1637.

1309 120. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. *Bulletin of the World*
1310 *Health Organization* 2003;2003:646-656.

1311 121. Belachew T, Nekatibeb H. Assessment of outpatient therapeutic programme for severe
1312 acture malnutrition in three regions of Ethiopia. *East African medical journal* 2007;84:577-588.

1313 122. World Health Organization. The treatment and management of severe protein-energy
1314 malnutrition. In: Geneva, Switzerland: WHO, 1981.

1315 123. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily Assessment of Pain in Adults with
1316 Sickle Cell Disease. *Annals of Internal Medicine* 2008;148:94-101.

1317